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ABSTRACT
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COMBINED CROSS-SECTIONAL PROSPECTIVE STUDY TO IDENTIFY BARRIERS TO
ADHERENCE OF PANCREATIC ENZYME USE IN PATIENTS WITH CF
by Clare Emma Pearson
Monitoring and adjusting dose requirements of  pancreatic enzyme replacement therapy
(PERT) are an integral part of the dietetic assessment of patients with CF. We wished to
characterize enzyme usage in our adult population and determine the extent to which
inappropriate enzyme usage contributed to poor nutritional and clinical state.
  Information was collected using a self-administered questionnaire developed to measure
patient   practice,   knowledge   and   beliefs   relating   to   PERT.   Exclusion   criteria   included
pancreatic sufficiency, <1500 U lipase/kg/d, and FEV1 <30%.
49  patients  completed the  questionnaire  (16-54y,  55%  male,   FEV1  31-125%).  67%  of
participants reported to never miss enzymes with meals; this was considerably lower for
snacks (35%). Those patients who omit enzymes with meals also missed enzymes with
snacks (r =30%, p<0.001). A more appropriate use of PERT was observed in patients with
lower as opposed to higher BMI. Despite intensive dietetic input 29% of patients missed PERT
with foods that contained fat and 20% of patients took PERT inappropriately with food that did
not contain fat.  The results identified 5 potentially better practices for measuring PERT
behaviour and knowledge.  In conjunction with their BMI and degree of gastrointestinal
symptoms risk for intervention can be assessed. 
The results showed underweight patients to have more optimal enzyme use, suggesting
greater dietetic involvement in these patients. Schall et al (2006) also found this to be the case
in children. The findings emphasised the need for targeted and effective input in patients
where problems are less obvious. The questionnaire has been a useful research tool, and has
been adapted as a screening tool for dietitians to gain a subjective perspective of patient’s
enzyme management and identify patients who need support. The combination of patient’s
PERT usage and their nutritional status could help capture and identify risk objectively and
quickly and allows resources to be allocated most effectively. 
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Cystic fibrosis (CF) is a genetic disease that typically produces malnutrition and chronic
respiratory infections (Wagener & Headley 2003). In the absence of a cure, treatment aims to
control   the   signs  and   symptoms   and   delay   disease   progression   through  a   series   of
interventions. Significant advances in the management of respiratory infection and pancreatic
insufficiency, coupled with advances in effective therapies by specialist multidisciplinary
teams, have resulted in a significant improvement in life expectancy to around 30 years
(Elborn 1998). 
The rationale for this project derived from a need to understand more about the management
of pancreatic enzme replacement therapy (PERT). It is also an area of professional interest
as during my time as a CF dietitian I have developed an understanding of the wider
implications of dealing with a chronic disease and the costs of relentless treatment regimens.
In doing research in this area it is important to measure both physiological outcomes and
relevant issues from the patient’s perspective of their overall wellbeing.
Since September 2001 I have been working as a dietitian within the Southampton Adult
Cystic Fibrosis Unit. We care for over 100 patients with CF from the South West region.
Dietitians are key members of the CF multidisciplinary team and play an important role in
helping   patients   with   CF   to   achieve   optimal   growth   and   nutritional   status.   Nutritional
requirements are increased in CF due to the extra energy demands of progressive lung
disease and the excess loss of nutrients in stools. The latter is due to pancreatic insufficiency,
present in up to 90% of patients with CF, and necessitates the use of PERT with all food and
drink containing fat. Effective treatment should allow a normal diet to be taken, control
symptoms,   correct   malabsorption   and   achieve   a   normal   nutritional   state   and   growth
(Littlewood & Wolfe 2000). Monitoring and adjusting enzyme dose requirements are an
integral part of the dietetic assessment. However, we may have a poor understanding of how
our patients manage their enzyme therapy in practice, making the advising and adjusting of
enzymes problematic for the dietitian. Currently there is little emphasis on the patient’s
adherence to the dosage and method of taking enzymes. Observing  patient’s  confusion
surrounding their PERT raised further questions around how patients manage their individual
needs.
In the absence of accurate information on what the patient is doing, the dietitian can never be
certain that the advice being offered are understood by the patient or are even the most
appropriate recommendations for the patients care. Measures of patient CF knowledge, their
1technical skills at administering PERT and dietetic methods of assessing the patient’s daily
PERT management are currently not available.
This raises the following questions:
• How do we determine whether patients are on the most optimal dose of PERT for
their requirements?
• How do we identify patients with poor adherence and does dietetic advice effectively
deal with these patients? 
• Is there an association between poor adherence to PERT and the effects on
nutritional status and disease progression?
• In what ways will this research change clinical practice?
These questions have been the focus of this research project. The aims are to explore the
relationship between attitude and behaviour as possible determinants of PERT adherence in
adults with CF. It is hoped that the outcome of the research will generate new theory to
support practice and provide a basis for future patient centered education programmes and
result in improved health care delivery.
The databases Medline, CINAHL (Cumulative Index to Nursing and Allied Health Literature)
and the Cochrane Database of Systematic Reviews for the period 1980-2006 were searched
using the keywords;  CF, pancreatic enzymes, adherence. Relevant articles were also
checked for further appropriate references.
2CHAPTER 1: REVIEW OF THE LITERATURE
The  purpose  of   this  chapter   is  to  examine   existing   work,   identify  areas  that   remain
unanswered and to explain the rationale for this research. The literature review starts with an
overview of CF management and the rationale for pancreatic enzymes in patients with CF. It
addresses the difficulties associated with the professional’s delivery and prescription of this
therapy. This is followed by a review of the theories and evidence on patient adherence and
behaviour towards enzyme therapy. The review ends with an overall summary, hypotheses to
be tested and aims of the present research.
1.1 CYSTIC FIBROSIS
CF is an autosomal recessive disorder. Affected individuals have two copies of a mutated CF
gene, one inherited from each parent. Mutations of the CF gene are most common in those of
white European origin, although CF has been described in almost all racial groups. In the UK
the incidence is 1 in 2500 births. The carrier risk is 1:25 (Peebles et al 2005). Most CF
patients are diagnosed in childhood. 
It is caused by mutations of the cystic fibrosis transmembrane regulator (CFTR) protein gene,
which functions as a chloride ion channel. This leads to pathological changes in organs that
express CFTR, including secretory cells, sinuses, lungs, pancreas, liver, and reproductive
tract (Ratjen & Döring 2003). Damage to the lungs predisposes to pulmonary infection and
inflammation and results in a productive cough, breathlessness and variable amounts of
sputum production. 
In addition to the lung and digestive problems, adulthood brings new complications, including
diabetes, liver  disease, renal failure, osteoporosis and reduced fertility, each requiring
considerable treatment in their own right. There are also the emotional stresses and strains of
living with a long-term, life threatening condition and its impact on education, careers,
relationships and families (page 9: CF Trust 2000). As survival has increased, the rewards of
effective and aggressive clinical treatment are becoming apparent. The challenge is to
improve life expectancy and quality of life. However, reported non-adherence to some
aspects of treatment is high (Abbott et al 1994) and there is a lot of interest in identifying the
potential reasons and consequences of poor adherence. 
The literature review focuses on the treatment regimens involving the CF dietitian, based on
existing guidelines and research. However, as these are only part of the treatment schedule
for patients with CF, a summary of the other significant regimens will precede this to
3appreciate   the   complex   and   laborious   managements   required   from   patients   and   why
adherence is an issue.
1.2 RESPIRATORY MANAGEMENT
The onset and intensity of the progressive lung disease in CF is highly variable. CF affects
both the upper and lower respiratory tract, from the nose and sinuses, right down into the
lungs. Most people with CF cough up mucus, wheeze or have trouble breathing. Blocked or
runny nose, sinus pain, nasal polyps and headaches are also common symptoms (page 28:
CF Trust 2000). Some patients report haemoptysis and chest  pain which can cause
considerable anxiety as a massive bleed can be life threatening.
The lungs become damaged because people with CF can’t clear all the mucus from the
airways.  The mucus is thick  because CFTR protein does not transport  chloride  ions
effectively. Although the airways of neonates with CF are not infected, chronic bacterial
infection with staphylococcus aureus, haemophilius influenzae and pseudomonas aeruginosa
occurs   early   in   life.   This   is   followed   by   chronic   inflammation,   ultimately   leading   to
bronchiectasis (Yankaskas & Knowles 1999).
Premature death from respiratory failure is the most common outcome for individuals with CF.
The prevention, eradication or delay of chronic infection of the lower airways is the most
important strategy to postpone this prospect. This can be achieved by optimal use of
antibiotics, appropriate airway clearance techniques, physical fitness and good nutrition
(Peebles et al 2005).
1.2.1 Physiotherapy
All patients with CF are recommended an individualised physiotherapy regimen. Chest
physiotherapy is the most time consuming feature of treatment and can be prescribed up to
four times daily for 20-30 minutes per session. It is required to reduce airway obstruction from
tenacious secretions, improve ventilation and delay the progression of the pulmonary disease
process. Forms of physiotherapy include:
• Advice on exercise and posture 
• Postural drainage and percussion
• The active cycle of breathing techniques (ACBT)
• Positive expiratory pressure (PEP)
• Oscillatory positive expiratory pressure (PEP)
4• Autogenic drainage (AD)
• Modified autogenic drainage
• High frequency chest wall oscillation (HFCWO)
• Intra pulmonary percussive ventilation (IPV)
Patients are also provided with personal exercise programmes addressing cardiovascular
fitness, strength and posture.
1.2.2 Inhalers, Nebulisers and Mucolytic Agents
Medication can be inhaled directly into the lungs by an inhaler or nebuliser. Each nebuliser
takes about 15 minutes to do and the majority of patients take two nebulisers per day
prophylactically. When unwell this can be up to six times per day. Inhaled bronchodilators
such as beta-agonists (e.g. Ventolin and Bricanyl) and theophylline widen the airways to
make it easier to breathe in and out. and improve mucociliary clearance. Inhaled anti-
inflammatory   agents   such   as   corticosteroids   (e.g.   Pulmicort   and   Flixotide)   reduce
inflammation in the airways, and mucolytic agents make the mucus in the lungs thinner and
easier to cough up (Cystic Fibrosis Trust UK and Solvay Healthcare Limited 2000).
1.2.3 Antibiotic therapy
Improved survival has been attributed to several factors, including the development of potent
anti-pseudomonal antibiotics (Elborn et al 1991; cited from Phelan et al 1979). The aim of
therapy is to reduce the burden of infection. Oral or intravenous antibiotic treatment are
administered during a respiratory exacerbation or as an elective course irrespective of clinical
state at regular intervals, for example three monthly (Peebles et al 2005). Patients at the
Southampton Adult CF Unit have their intravenous antibiotics either at home or in hospital
and a standard course are 4 infusions daily for 10-14 days. Antibiotics often cause the
patients to experience side effects such as abdominal pain, loose stools, nausea, vomiting,
rashes, itching, dizziness and altered taste. Aminoglycosides can cause long term potentially
irreversible damage to hearing and induce renal failure.
1.2.4 Summary
Despite the likelihood of side effects, patients usually feel significantly better post antibiotic
therapy and adherence rates have been shown to be 80-93% (Conway et al 1996, Passero et
al 1981, Meyers et al 1975). Physiotherapy and nebulisation is more problematic as these are
time-consuming and patients often report no short-term benefit. In studies adherence rates
have varied between 40-53% (Abbott et al 1994, Conway et al 1996, Passero et al 1975).
51.3 NUTRITION  
This section provides an overview on the importance of nutrition in CF, dietary requirements,
recommendations for advice given and how this is delivered to patients. 
Although prognosis for survival is related most directly to respiratory status, studies have also
shown a close relationship between nutrition and survival rates. Gaskin et al (1982) found
that CF patients with normal fat absorption maintain a better pulmonary function than their
counterparts with steatorrhoea, and seemingly have a better prognosis. Females with
steatorrhoea had a progressive deterioration in their ideal weight for height concomitant with
a fall in pulmonary function. At the time of this study is was unclear the extent to which
nutritional factors contributed to prognosis. A later cohort of 3298 German patients did
however show that nutrition and lung function are co-dependent variables in CF (Steinkamp
et al 2002). Patients with normal weight had a significantly smaller decrease in lung function
over a 2-year period than those with malnutrition and this was shown in all age groups. A fall
in weight for height of 5% predicted or more within 1 year was associated with a parallel
decrease in FEV1, whereas patients with improved nutrition showed constant or even
improved FEV1. 
Cystic fibrosis is a multifactorial disease, which makes it difficult to allocate the causes of
malnutrition from disease. Although a causal association between nutrition and lung function
are well accepted, it is less clear whether poor nutritional status leads to a decline in lung
function or whether worsening pulmonary disease influence nutritional status. It is likely that
these variables are inter-dependent.
It is interesting to note that despite improved pulmonary function and survival being strongly
associated with better nutritional status, not all patients with CF have a satisfactory weight.
The UK CF Database 2004, showed that 15% of children were <5
th height centile and 12%
<5
th weight centile. For adults, 16% <5
th height centile and 20% <5
th weight centile.
1.3.1 Nutritional requirements
A variety of factors contribute to an energy deficit in patients with CF. 
Increased stool energy losses
The availability of energy ingested from the diet is often limited in CF due to pancreatic
insufficiency. If untreated, maldigestion and malabsorption of nutrients results in abdominal
pain, increased stool frequency and steatorrhoea.  However, there is good evidence by
6Murphy et al 1991 that even in patients who are symptomatically well controlled on pancreatic
enzyme replacement have raised stool energy losses which may contribute towards an
energy deficit sufficient enough to limit growth.
Increased energy demands of progressive lung disease
Increased resting energy expenditure can be another factor contributing to the energy deficit
in CF. The gene defect, the consequences of chronic pulmonary infection, and altered lung
mechanics have been described as possible mechanisms (Bell et al 1996). Fried et al (1991)
found that increased resting energy expenditure in male subjects with CF appears more
closely associated with declining lung disease than with genotype. 
Anorexia and poor energy intake
Due to the pathological consequences of CF, patients are at risk of poor appetite and
insufficient dietary intake, which can result in abdominal pain, vomiting after excessive
coughing,   constipation,   abdominal   pain,   bloating,  distal  intestinal  obstructive   syndrome
(DIOS) and respiratory symptoms of breathlessness. For those patients with mild to moderate
pulmonary disease an infective exacerbation has a short-term effect on appetite and weight
and once recovered they soon return to their usual status. However, patients with severe CF
and / or several infective respiratory exacerbations close together, struggle to reverse the
weight loss which then has consequences on infection. 
Two other factors seen in adolescent and adult patients are diabetes mellitus and cholestatic
liver disease. Diabetes can increase calorie losses as a result of glucosuria. Liver disease
with   focal   biliary   cirrhosis   may   exacerbate   the   severity   of   malabsorption   because   of
inadequate bile acid secretion (Ramsey et al 1992).
1.3.2 Nutritional recommendations
Traditionally a low fat, carbohydrate dense diet was prescribed for patients with CF with the
rationale that reducing dietary fat would improve bowel symptoms and reduce stool bulk. It
was not until 1988 that Corey et al demonstrated that a high fat, high calorie diet promoted a
normal growth pattern and improved survival.  It is widely accepted among CF centres that
energy intake should exceed normal requirements and that patients with CF require 120 –
150% of the recommended daily intake for age and gender (Mac Donald 1996). However
studies have shown that many patients fail to meet the CF dietary recommendations
(Borowitz et al 2002). An equation has been developed incorporating increased resting
7energy expenditure and other factors in order to estimate the energy expenditure specifically
for  CF   patients  (See   Appendix  1).   It  makes allowances   for  disease  severity,   activity
coefficiency and pancreatic insufficiency, however these indices vary considerably between
individuals hence requirements must be interpreted with caution. It is our practice to estimate
individual requirements using the above methods but in practice, recommendations are
based more on clinical judgment informed by changes in weight and therefore BMI.
The UK Cystic Fibrosis Trust Nutrition Working Group published a nutritional management
consensus report in 2002. The recommendations relevant to adults are in Appendix 2.
Nutritional support progresses in three stages depending on individual clinical needs and
what has previously been tried. Initially all patients are educated on dietary manipulation
which involves advising patients and relatives on ways to fortify meals with energy dense
products such as cheese, cream and margarine. For the majority of patients this is sufficient
to maintain an ideal weight. In adults, the use of nutritional supplements is indicated when the
patients BMI is below 19kg/m² or if there has been more than 5 per cent weight loss over
more   than   two   months.   There   is   an   extensive   range   of   supplements   available,   the
prescription of which is based upon individual requirements and taste preference. 
It is generally accepted that the requirements for fat-soluble vitamins are raised in CF due to
pancreatic insufficiency and malabsorption. Vitamins A, D and E are given routinely in
patients   with   pancreatic   insufficiency.   Appendix   2   includes   details   on   the  vitamin
recommendations set by the UK Cystic Fibrosis Trust Nutrition Working Group (2002),
Plasma levels of vitamin A and D often remain low despite being on the above recommended
therapy.   Some   CF   centres   would   attempt   to   correct   these   deficiencies   with   further
supplementation, however research at Southampton has made us more cautious due to the
possibility of accumulation of vitamin A in the liver, which would cause hepatic toxicity.
(Cawood et al 2003).
As is the case with PERT, adherence to vitamin supplementation is difficult to determine and
rather than automatically increasing the dose on evidence of deficiency, it is important to
gauge   whether   or   not   this   therapy   is   being   taken   effectively   and   routinely.   Routine
supplementation of water-soluble vitamins is unnecessary.
81.3.3 Role of the dietitian
Newly diagnosed and recently transferred patients are given a comprehensive nutritional
evaluation. This also occurs for each patient at his or her annual review. The assessment
includes:
• Anthropometric measurement – weight, height, BMI
• 5 day food diary and computerized analysis
• Review of pancreatic enzyme therapy (if applicable)
• Serum levels of vitamins and trace elements
• Oral glucose tolerance test
• DEXA scan to detect or monitor osteopenia / osteoporosis
Patients typically have contact with the dietitian at all 3-monthly outpatient clinic visits,
admissions to hospital and ad hoc reviews if needed. The dietitian then provides on-going
nutritional assessment and support relevant to the needs of the individual, which involves the
following:
• Monitor nutritional status at each clinic visit/admission
• Encourage a regular intake of energy dense meals and snacks to meet estimated
requirements
• Advice on the titration of pancreatic enzyme replacement therapy to minimise stool
energy losses
• Advice on vitamin and mineral supplements
• Encourage a positive attitude to eating and mealtimes
• Advice on nutritional supplements or enteral tube feeding when normal foods cannot
meet estimated energy requirements
Particular situations require more intensive dietetic support, for example, during infective
exacerbations, transition from paediatrics to adults, pregnancy, CF related diabetes, enteral
feeding, eating disorders and pre-and post lung transplantation. Clinical assessment of
nutritional status is done primarily by anthropometry. Weight and if required, height, are
methods that can be measured easily and quickly at the beginning of each consultation. From
this, the body mass index (BMI) (weight[kg]/height[m]²) can be calculated to assess whether
body weight is in proportion to height and the status of the individual i.e. underweight, ideal,
overweight. (See Appendix 3). 
91.3.4 Summary 
The practical application of nutritional therapy has been aided by the CF Trust standards
document, however this is by no means comprehensive. Gaps exist where there have been
deficient or inconclusive studies. There are specific aspects of CF nutrition that have received
a lot of attention, particularly diabetes and osteoporosis. A consensus document on the
‘Management of Cystic Fibrosis related Diabetes Mellitus’ was produced in June 2004 and a
publication on bone health is due to follow. In the UK, dietitians do not appear to have been
involved in studies on adherence, whereas in the US there has been more focus on this.
(Brady et al 1992). 
Despite frequent nutritional advice, there continues to be a proportion of patients that fail to
achieve their ideal weight. Of concern, is that some of these patients only have mild to
moderate lung disease and that other factors predispose their inability to achieve a realistic
weight. Reasons for this may be insufficient enzyme use, poor adherence to nutritional
support, body image issues and the financial costs of purchasing food. Strategies used to
increase weight include prescribing supplements and enteral feeds rather than solving the
causes of the problem. Paediatric dietitians may be more familiar with the behavioural
aspects of nutrition but in adults it is more difficult to challenge patients on issues surrounding
eating and adherence. There is no doubt in the literature that disease-related factors
contribute to nutritional status, however behavioural factors tend to be overlooked probably
because these are more difficult to quantify and address.
1.4 PANCREATIC INSUFFICIENCY
CF affects the digestive system in several ways, but the most significant and almost
invariable effect is on the pancreas. The pancreas has two main functions of enzyme
secretion and hormone production. Normally the pancreas secretes the digestive enzymes
lipase, amylase and protease. These break down fat, carbohydrates and protein into small
absorbable components. A reduced volume of pancreatic secretion with low concentrations of
bicarbonate cause the digestive enzymes to be retained in the pancreatic ducts and
prematurely inactivated, ultimately leading to tissue destruction and fibrosis (Ratjen and
Döring 2003). The consequence of this is maldigestion and malabsorption of nutrients,
particularly dietary fat and fat-soluble vitamins. Clinical signs of pancreatic insufficiency
include  the frequent passage of large bulky greasy stools, recurrent abdominal pain and
worsening malnutrition.
10As knowledge of CF mutations is accumulated, greater insight into genotype-phenotype
relationships exists. From a dietetic viewpoint the ∆F508 mutation is closely linked to poor
pancreatic   function   (pancreatic   insufficiency).   Specific   mutations   of   the   CF   gene   are
associated with pancreatic sufficiency (See Appendix 4). Someone with two ∆F508 mutations
is likely to need pancreatic supplements, but if there is only one ∆F508 mutation – or none at
all – it is possible that the pancreas will still produce sufficient enzymes to digest the food
(page 22: CF Trust 2000).  Approximately 85% of the CF population is pancreatic insufficient
and require oral enzyme capsules to aid digestion and absorption of nutrients. If inadequately
treated, high stool energy losses will occur which may compromise nutritional status and
prognosis (Murphy et al 1991). Pancreatic functional status is a strong predictor of long-term
outcome and has a direct influence on nutritional status (Gaskin et al 1984). Therefore
knowing the genotype is useful not only for nutritional management but also as a prognostic
indicator.
1.4.1 Direct tests of exocrine function
Overt fat malabsorption does not occur until approximately 85-90 per cent of the function has
been lost. This large reserve of pancreatic function means that any pancreatic function test
based upon the measurement of either pancreatic enzymes or their breakdown products is
insensitive (Kumar & Clark 2002).
Secretin-cholecystokinin test
Duodenal intubation tests are considered the most accurate to assess pancreatic function
and the secretin-cholecystokinin is the most commonly used direct test. The pancreas is
stimulated by intravenous secretin and cholecystokinin or cerulein. The aspirate is assessed
for amylase, trypsin, chymotrypsin, lipase, and bicarbonate. Despite being considered the
‘gold standard’, these tests are not widely used in clinical practice because of its complexity,
cost and invasiveness (Beharry et al 2002). 
1.4.2 Indirect tests of exocrine function
Faecal fat estimation
The standard test for measuring faecal products of maldigestion is the three-day stool
collection with the patient on a diet containing over 100g fat per day. Faecal balance studies
remain the most useful clinical tool for establishing a diagnosis of pancreatic insufficiency and
for monitoring a response to enzyme therapy (Durie et al 1998). This test is not without its
limitations; it has been described as cumbersome and non-specific, as it is prone to
inaccurate results caused by errors in stool collections and recording of nutrient intake
11(Beharry et al 2002). The test lacks specificity and is unable to differentiate between
pancreatic, biliary or intestinal causes of nutrient absorption. Although used in many CF
centres, the test has been withdrawn at Southampton University Hospitals mainly because
stool collection is difficult and unpleasant for patients. 
Faecal chymotrypsin
Pancreatic enzymes such as trypsin and chymotrypsin have been measured in faeces using
highly specific synthetic substrates. Faecal chyotrypsin is more reliable than trypsin because
it is liable to proteolytic degradation by pancreatic enzymes and colonic bacteria. With
insufficient   treatment   faecal   chymotrysin   values   are   low,   indicating   either   inadequate
prescription or patient noncompliance. Unfortunately, a normal value does not exclude
significant steatorrhoea (Littlewood & Wolfe 2000). 
Faecal elastase
More recently, the faecal elastase-1 method has been developed to measure human
pancreatic elastase in faeces. Patients can remain on their pancreatic enzyme supplements
because it does not cross-react with the porcine supplement and it correlates well with
stimulated pancreatic function tests (Cade et al 2000). The stool sample is a 1g sample and
levels of <200µg/g stool suggests pancreatic insufficiency. However, the faecal elastase level
does not necessarily correlate with severity of symptoms. 
Beharry et al (2002) found faecal elastase a useful screening test of pancreatic insufficiency
in patients who had previously been characterized by other tests of pancreatic function
including the 72-hour faecal fat balance studies, pancreatic stimulation test and / or serum
trypsinogen. The study was however unable to demonstrate a correlation between faecal
elastase-1   concentration   and   the   severity   of   fat   maldigestion   among   individuals   with
pancreatic insufficiency. Carroccio et al (2001) found that in CF children faecal elastase-1 is
slightly more accurate than faecal chymotrypsin determination in the diagnosis of pancreatic
maldigestion. A limitation of this study was that the accuracy of  these indirect tests was not
compared with the gold standard secretin-pancreozymin test.
Faecal weight 
An alternative simplistic method of detecting maldigestion is using faecal weight. Murphy et al
(1991) found that the energy content of the stool remains relatively constant (8kJ or 2kcal of
energy present in each gram of wet stool). Although this continues to be unpleasant for
12patients, it does not rely on laboratory investigation and analysis. For this test to be of value
guidance on interpreting values for clinicians, as well as protocols to ensure the process is as
dignified as possible for patients.
 
Faecal microscopy
Faecal microscopy can be used as a minimum measurement of steatorrhoea. It is a semi-
quantitative estimate of faecal fat content that has been validated by comparison with
quantitative measurements. Microscopy of a faecal sample can identify severe steatorrhoea
due to the presence of an excess of neutral fat seen at microscopy.
Acid steatocrit
Acid steatocrit is another semiquanitative measure involving acidification of the faecal
homogenate.   It  cannot  reliably  quantitate exocrine  pancreatic reserve  in  patients with
pancreatic sufficiency. Qualitative tests, such as microscopic examination of the stool or
steatocrit, provide limited information since they fail to account for faecal losses of nutrients in
relation to intake.
Oral pancreatic function tests
Breath tests rely on the principle that specific by-products of maldigestion may be emitted in
exhaled breath. These tests have no clear defined clinical use but may have applicability as a
research tool.
PABA - test
A synthetic compound (N-benzoyl-L-tyrosyl-para-aminobenzoic acid) is cleaved by pancreatic
chymotrysin within the intestinal lumen releasing the marker para-aminobenzoic acid (PABA).
PABA is excreted in the urine, where it can be measured. The test is time consuming but is
specific for pancreatic insufficiency, with a 65-80% sensitivity (Kumar & Clark 2002).
1.4.2 Clinical application of pancreatic function tests
An unpublished survey completed by 62 dietitians from UK hospitals by Wasling in 1992
(discussed in a paper by Leonard & Knox 1997) highlights the diversity of methods used to
assess requirements for PERT. PERT was primarily directed towards the symptomatic
correction of steatorrhoea, abdominal pain relief, and reduction in stool frequency and stool
bulk. Only 12% carried out faecal fat assessments and even fewer carried out other
laboratory tests or stool weight measurements.
13Adult patients are often reluctant to provide stool samples in addition it can take several
weeks to get the results back due to the lab waiting to run the test in batches. At our centre,
tests such as faecal balance studies are rarely used to monitor response to enzyme therapy.
Without access to specific tests, enzyme therapy can only be adjusted based on subjective
valuation where descriptions of bowel habits are reported by patients and interpreted by the
clinicians. Bowel habit questionnaires have been developed, although these are more
orientated towards the assessment of paediatric patients.
In summary, there is a large range of investigations into maldigestion, however their use in
clinical practice is limited. Assessment of maldigestion, adequacy of enzyme prescription and
adherence to PERT is therefore not readily available or reliably tested. Once the faecal
elastase test has identified those patients who are pancreatic insufficient, little else is
routinely available in clinical practice. Tests that assess the effectiveness of enzyme therapy
would be of great value to the CF dietitian and other members of the team involved in
advising on PERT use. Littlewood & Wolfe (2000), in a review of malabsorption in CF, state
that it is essential that patients treated with pancreatic enzymes have some periodic
measurement of the adequacy of the pancreatic replacement therapy, over and above clinical
symptoms, bodyweight and growth, which do not always correlate with the severity of the
malabsorption. However, in CF enzyme treatment is usually prescribed on the basis of growth
and symptoms. This requires a certain amount of trial and error, as there is no easy reliable
and universally accepted test to measure enzyme requirements.
1.4.3 Treatment preparations
On evidence of intestinal malabsorption, via a positive faecal elastase, oral supplements of
pancreatin are introduced to compensate for reduced or absent exocrine secretions. The
dose should be varied depending on the fat content of the meal, snack or drink.  Major
advances have been made over the last 20 years in pancreatic enzyme preparations. ‘High-
dose’ enzyme capsules were introduced in 1992/93, ranging from 22,000 – 25,000 units of
lipase per capsule. More recently, Creon 40,000 has been brought onto the market, and now
pancreatic enzyme supplements are available in strengths ranging from 5000 to 40,000 U
lipase per capsule. Higher dose preparations mean that patients can take fewer numbers of
capsules although they are greater in size. 
14Traditionally, powder-based and enteric-coated tablet preparations were used but these have
largely been replaced by the enteric-coated microsphere preparations (See Appendix 5). The
enteric coateing aims to prevent them from being dissolved in the acidic environment of the
stomach. Instead the enteric coating is usually broken down in the duodenum where food
begins the process of digestion. The duodenum is less acidic than the stomach, but if the
pancreatic fluid is low in bicarbonate and does not neutralize the acid entering the duodenum
from the stomach, the enteric-coated capsules may not dissolve properly. Some patients
therefore require proton pump inhibitors to reduce the amount of stomach acid (page 48: CF
Trust 2000). However a Cochrane review by Ng & Jones (2003) found limited evidence to
suggest that agents that reduce gastric acidity in people with CF are associated with
improvement in gastrointestinal symptoms or fat absorption.
Pancreatic   supplements   do   not   usually   completely   normalize   fat   absorption   as   the
bioavailability of pancreatic enzymes in CF is affected by many factors. These include the
rate of gastric emptying, gastric acid output, time of ingestion of the capsules in relation to a
meal, low intestinal pH, small bowel motility and the characteristics of the intestinal mucus. It
is therefore not surprising that increasing the dose of pancreatin is not always matched by a
corresponding increase in effectiveness.
Accurately calculating patient’s lipase requirements is also difficult. Firstly, the stated capsule
dose is based on the minimum capsule contents at the end of the shelf life. Enzyme
degradation occurs during storage, therefore capsules are overfilled, but the extent of this is
variable between products and in comparison to patients with pancreatic insufficiency due to
other aetiologies, CF patients are particularly difficult to treat (Durie et al 1998). Secondly, a
poor correlation exists between symptoms and the objective measurement of steatorrhoea,
with some patients appearing to tolerate quite substantial fat losses with neither symptomatic
complaint nor evidence of impaired growth. Without enzymes, pancreatic insufficient CF
patients show considerable variation in fat absorption: some individuals lose as much as 40%
of their fat intake, while others may only lose 20% (Dodge 1995). Individual requirements for
PERT therefore vary greatly and a single standard enzyme dose is not feasible. 
Titrating the dose of enzymes more closely in accordance to the approximate fat content of
food is becoming part of the education process for some centres, although this is currently
not the practice at Southampton. 
151.4.4 Timing
The Nutritional Management of Cystic Fibrosis consensus guidelines (CF Trust 2002)
provides no guidance on the optimal timing of doses with food and drinks. Taylor et al (1999)
showed that there is considerable individual variation in mixing, gastric emptying, and
intestinal transit of food and pancreatin. Their recommendation was that patients should
spread their pancreatin dosage throughout the meal. 
There are limited studies into the optimal timing of PERT. Many of the recommendations in
the literature are based upon expert opinion rather than evidence based. For example, the
consensus report on nutrition for pediatric patients with cystic fibrosis (Borowitz et al 2002)
recommend that enzymes are most effective when taken before each meal and snack; the
Australian Clinical Practice Guidelines say to take enzymes before, or before and during, a
meal or snack as enzymes are most effective for up to 30 minutes after consumption
(Stapleton et al 1999).
Inconsistent recommendations for the optimal timing for PERT are likely to explain the
variation seen in patient practice. A study by Jones & Lewis (1996), found a great deal of
variance on when patients took their enzymes. Abbott et al (1994) showed that the majority
took their enzymes throughout the meal (53%) while the rest either took them at the
beginning or end of the meal. More studies are needed to determine whether this is a true
representation of practice across the UK as it is more than ten years on from when these
studies were done. 
1.4.5 Method of administration
Infants
Enteric-coated enzyme granules, microspheres or mini-microspheres can be administered via
a teaspoon at intervals throughout the feed, mixed with a little milk or pureed fruit (CF Trust
consensus guidelines 2002). Initial dosages of ¼ standard strength capsule (5,000 – 10,000
IU lipase per capsule) per 60 – 120ml formula feed, or per breastfeed, can be offered and
individually titrated against symptoms of malabsorption (CF Trust consensus guidelines
2002).
Older infants and young children
Initial doses of 1 – 2 capsules of Creon 10,000 or Pancrease per meal and a half to 1 capsule
with fat containing snacks (Littlewood & Wolfe 2000). The capsule should be swallowed
16whole at as early an age as possible and many children will manage this by 3 or 4 years,
some very much earlier (Littlewood & Wolfe 2000).
On average, infants and young children require higher doses of pancreatin/kg body weight
than older children and adults. This reflects their higher fat intake (5 g fat/kg/day compared
with the average adult intake of 2 g fat/kg/day). Traditionally, enzymes have been prescribed
on the basis one dose for meals and a smaller dose for snacks (CF Trust 2002). 
Adolescents and adults
No specific recommendations are made for PERT in adolescents and adults in the ‘Nutritional
management of cystic fibrosis’ CF Trust 2002 document. The same principles for children
therefore apply to adults.
Clinical application
Earlier in this chapter the guidelines and theory behind prescribing PERT were discussed.
The above guidelines appear straightforward in theory, however the issue of prescribing
PERT is complex and dependent on many factors. In order to better understand the process
through which a patient approaches PERT usage, a causal chain was developed.  (See
Figure 1.1).
Figure 1.1: Theoretical model of prescription
Prescription
(What they should do)
Patient direction
(Say they do)
Patient usage
(Actually do)
Outcome
(Consequence)
17The model shows that there are many factors that influence the outcome of treatment. For
example, patients maybe reluctant to adjust their enzyme dose if they are worried about the
possible consequences (i.e. increased bowel frequency and abdominal pain). What patients
say they do and what patients actually do are two important stages, which requires further
investigation. Thorough examination of each stage highlighted that you cannot assume that
patients adhere to the clinician’s recommendations. 
Although our advice is directed towards improving patient care, it is dependent on the
willingness and motivation of patients to follow recommendations. From clinical experience, it
appears that some patients may be resistant to making changes to their long-term therapy.
Little consideration is made to distinguish whether this resistance is as a result of the patient
having   insufficient   knowledge   or   the   inability   to   make   a   behaviour   change.   A   better
understanding of the behavioural aspects of CF non-adherence to PERT may improve the
effectiveness of dietetic consultations and therefore requires investigation. 
1.4.6 Side effects of PERT use
Pancreatin can irritate the perioral skin and buccal mucosa if retained in the mouth, and
excessive doses can cause perianal irritation (BNF). Until the 1990s, the reported side effects
of pancreatic enzymes were minor. In the US, supplements were classified as food additives,
and in the UK they were licensed as pharmacy medicines and did not require a prescription
(Bakowski & Prescott 1997). 
1.4.7 Fibrosising colonopathy 
Fibrosing colonopathy (FC) is a gastrointestinal condition first described by Smyth et al in
January 1994. They reported five cases of fibrotic strictures of the ascending colon in children
with CF, and proposed a causal relationship between strictures and use of the newly
available high strength pancreatic enzymes, which had been initiated 12-15 months prior to
the time of presentation. Further observations of FC were seen in patients from other
hospitals also on high strength pancreatic enzymes (McHugh et al 1994, Oades et al 1994,
Campbell et al 1994, Mahony & Corcoran 1994). Its incidence was later reported in patients
on low-strength enzyme formulation but in high quantities (Jones et al 1995, VanVelzen
1995). 
An epidemiological case control study followed on the 14 children identified with FC in the
UK, and although small in numbers showed that they had been receiving (mean intake of
46,200 IU lipase/kg/d compared with controls of 21,500 IU lipase/kg/d) (Smyth et al 1995).
18The study reported an association with high doses of pancreatic extract and the relatively
new high strength pancreatin preparations.  An American study reported on 29 confirmed
cases of CF patients with FC with a higher mean intake (50,046 IU lipase/kg/d compared to
18,98I5 IU lipase/kg/d in controls). They found no association between the use of certain
types of high strength pancreatic enzyme preparations and FC (FitzSimmons et al 1997).
However FC cases had higher rates of gastrointestinal complications and more long-term use
of H2- receptor blockers, corticosteroids and dornase alfa.
Controversy still exists as to whether the pathogenesis of this disorder is due to excessive
quantities of lipase (Smyth et al 1994) high strength enzymes, or due to the methacrylic acid
copolymer coating on certain brands of enzyme preparation, which may be toxic to the
colonic mucosa (Van Velzen 1995). Alternative theories include chronic ischaemia (Briars et
al 1994), an immunological disorder (Lee & Durie 1997) or presence of malabsorbed fat in the
colon (Dodge 1996). 
The UK Committee on the Safety of Medicines (CSM, 1995) advised that Pancrease™ HL,
Nutrizym™ 22 and Panzytrat™ 25 000 is no longer be indicated for children aged <15 years
with CF. The committee also recommended that ‘it would be prudent for patients with CF not
to exceed 10,000 IU lipase/kg/day regardless of which preparation is used’.   In the US,
FitzSimmons et al (1997) recommend that enzyme doses should be less than 2500 U
lipase/kg per meal or less than 4000 U lipase/gram fat per day to avoid FC.
Only 3 children in the UK have developed FC since 1995, and all had received Nutrizym™GR
granules at dosages well in excess of 10,000 IU lipase/kg/d (Littlewood & Wolfe 2000).
Despite the rarity of this condition, its occurrence has had major implications on prescribing.
As a result, some centres have changed their approach to prescribing enzymes by reducing
dosages in attempt to meet recommendations. Littlewood (1996) believes that a proportion of
cystic fibrosis patients who are taking in excess of 10,000 U of lipase/kg/day do not require
such high doses. In patients who are well, asymptomatic and growing normally, an attempt
should be made to reduce the dose. If absorption is satisfactory (fat absorption over 85% or
no neutral fat and little split fat on microscopy), the dose of enzyme should be reduced
gradually by 10% every few weeks. If symptoms occur or weight gain is adversely affected
the previous dose should be resumed. Absorption is again checked. If the dose is still
substantially over 10,000 U lipase/kg/day a drug to reduce gastric acid should be added.
Further   enzyme   reduction   can   then   be   attempted   while   taking   regular   ranitidine   or
omeprazole. Following the above Leeds regimen, 66 (47%) of 139 pancreatic insufficient
19children attending Leeds CF clinic are still taking more than the dose recommendations of
10,000 U lipase/kg/d but only 18 (13%) take more than 15,000 units and only 4 (3%) more
than 20,000 U lipase/kg/d.
In an attempt to reduce the risk of FC and meet CSM recommendations, two studies by
dietitians attempted to reduce doses of pancreatic enzymes supplements in cystic fibrosis
patients. Both studied children and focused on whether reducing enzymes had implications
on growth. Lowdon et al (1998) had 40% of patients exceeding 10,000 U lipase/kg/day prior
to the start of the study. Fifteen out of the twenty-one participating children managed to
reduce their dose from a mean 18,380 to 864 U lipase/kg/day. There were no significant
changes in energy or fat intake, but there were significant increases in weight and height SD
score and weight/height ratio. The study by Beckles Willson et al (1998) resulted in the mean
enzyme dose being reduced from 26,500 to 12,600 U lipase/kg/day. Again, mean energy and
fat intakes were unchanged during the study. There was no difference in mean height gain.
Intervention during a research project may not replicate usual dietetic practice. Both studies
acknowledge that patients received tight supervision and dietetic intervention, which may
have resulted in more appropriate usage. 
Despite increased efforts, neither study managed to reduce enzyme intakes in all patients.
Beckles Wilson et al took the positive approach that they successfully reduced pancreatin
dose by 50 per cent and that 21 of the 25 patients reached their target of <15,000 U L/kg/day.
However, this is above the CSM recommendations of less than 10,000 U L/kg/day, which
only 8 patients (32%) from this particular study achieved. The Lowdon study managed better
with 15 (71%) children reducing their lipase dosage to the recommended level. The remaining
6 patients (29%) were unable to reduce their dose of PERT (3 of which ‘refused’). The total
average from both studies for patients who managed to reduce lipase units to meet CSM
recommendations was 51%. There is no follow up data to show if these patients managed to
stay at the lower post intervention dose levels. Therefore, despite regular dietetic intervention
it appears that patients did struggle to meet CSM guidelines. It also raises the question as to
whether CSM recommendations are achievable, practical and realistic.
In summary, there have been only two published attempts to reduce pancreatic enzyme dose
down to CSM recommendations and this did not include adults. Weight, height and nutrient
intake were the only measured outcomes post dose reduction. Unfortunately neither paper
gave an insight into problems that may have occurred as bowel habits, abdominal symptoms
and stool lipid losses were not reported, measured or monitored. No attempts appear to have
20been made to assess changes in abdominal pain, stool frequency and formation. Lowdon et
al (1998) measured the lipid content of wet stools once the recommended dosage of PERT
was achieved. The mean result was a coefficient fat absorption of 91.9%. Stool lipid levels
were not measured pre-intervention therefore we are unable to determine whether fat
absorption decreased due to a reduction in PERT.
It is possible that during both trials attention to matching pancreatin dose more closely to fat
intake may have been the factor that helped patients, thus improving absorption. The study
does not exclude that patients may have improved the timing of enzymes, varied the dose
more accordingly to fat intake or become more compliant during the trial. Patient feedback
could have provided an insight into how they found the process of reducing their enzyme
intake. Did they find it difficult? Were they worried about altering their therapy and the
possibility of increased steatorrhoea? How did they know when they were at the right dose?
Did they experience changes in bowel habits? Neither study considered the possibility on
patient non-compliance. Did they understand the advice they were given? Did they adhere to
it? Did they find it ineffective and change back to what they were previously doing? Did
patients actually reduce their PERT or just say they did?
The studies provide no insight for colleagues on how to best manage those who do not meet
the CSM criteria of using less than 10,000 UL/day. From attending the UK CF Dietitians
Interest Group meetings, the general consensus is that clinicians are not strictly implementing
CSM guidelines. However there remains a sense of erring on the side of caution. This
approach to not restricting PERT is not endorsed by majority of specialist centres, although
this assumption is based on opinion rather than evidence. There appears to be no plans for
the CSM recommendations to be amended. 
For many years patients have been encouraged to increase their intake of enzymes
according to clinical response. Patients requiring large doses of enzymes have generally
been changed to high-strength preparations (25,000 and 40,000 U lipase). However, after
conversion, some patients are accustomed to taking large numbers of capsules with each
meal.  FC is one of many gastrointestinal complications, constipation and DIOS occur
frequently in the CF population and this can be attributed to too few pancreatic enzymes.
Hence a fine line exists for those involved in the adjustment of PERT; over-prescribing could
lead to FC whilst under-prescribing could lead to malabsorption, malnutrition, constipation
and DIOS. It raises the question as to how seriously should we take these recommendations.
21Recommendations were based upon opinions from expert committee and findings from a
controversial paper. The evidence base is not from random controlled trial or prospective
studies and there remains no consensus among clinicians.
A review of the literature revealed no reported incidences of FC in adults with CF. However,
the CSM do not distinguish their recommendations between adults and children. Adult
patients are major users of high-strength pancreatic enzymes (25,000 and 40,000 units of
lipase) in view of the convenience. The UK CF database revealed that a high proportion of
patients exceeded the10,000 U lipase per kg per day recommendations proposed by the
CSM.  This suggests that clinicians appear to be moving away from the restrictive use of
enzymes due to them finding it difficult to control steatorrhoea within these guidelines. It
therefore raises the question as to how relevant the guidelines are particularly for adults. In
2002, Solvay brought out Creon 40,000 and there remained some hesitancy about using high
lipase  products  at   the  UK  Dietitians  CF  Interest  Group  meetings.   Following   personal
communication with Solvay, they reported no adverse problems associated with Creon
40,000. They were also able to provide me with prescription details; approximately 125000
prescriptions for Creon 10,000; 50,000 prescriptions for Creon 25,000 and only 15,000
prescriptions for Creon 40,000. It shows that Creon 40,000 is used much less than the other
doses in the UK. There are no studies as to why this is the case but possible explanations as
to why this is the case could be that patients prefer to swallow smaller capsule sizes and that
clinicians are hesitant to exceed the CSM guidelines. 
1.4.8 Other Gastrointestinal problems
As the CF population ages, other gastrointestinal problems unrelated to malabsorption may
manifest e.g. inflammatory bowel disease, constipation, peptic acid disease, coeliac disease,
lactose   intolerance   and   irritable   bowel   syndrome.   The   associated   symptoms   may   be
misinterpreted by the patients and may be linked to a problem with pancreatic enzyme
dosage instead. It has been suggested in the literature that a change in enzyme dosage is
often based upon GI symptoms rather than malabsorption or low body weight.
1.4.9 Summary  
Despite PERT becoming a more sophisticated and effective therapy over the years, clinicians
still approach this therapy with caution and uncertainty. There is considerable literature
available on pancreatic enzyme therapy between the years 1994 and 1998 but this largely
focuses on the occurrence of FC. In view of the serious consequences of this condition and
the ongoing debate regarding the pathogenesis, it has received considerably more attention
22than other, more frequently occurring, gastrointestinal conditions in CF such as constipation
and DIOS., The evidence from the UK CF database shows that a vast proportion of patients
exceed 10,000 U L/kg/d and that FC has never occurred in the adult CF population, CSM
recommendations are still widely reported (including in the BNF) despite the fact that there
have been no recent reports of FC in the UK.
Tests are available to diagnose pancreatic insufficiency but thereafter, there is a distinct lack
of tools to monitor the effectiveness of pancreatic enzyme dose. The dietitian is therefore
dependent   on   the   patients   reporting   details   of   their   enzyme   use   and   description   of
gastrointestinal symptoms. Pancreatic enzyme supplements are listed as a prescribable drug
but in practice it is taken with food and tends to be considered more as a nutritional
supplement. Dietitians have therefore taken on the role of adjusting doses of PERT and
advising on its use without the ability to prescribe. However, uncertainty remains as to how
effective maldigestion is controlled by PERT, one factor being the lack of knowledge as to
whether patients are under or over dosing on their enzymes.
1.5 DESCRIBING COMPLIANCE AND ADHERENCE 
The effectiveness of PERT is dependent on two factors: the efficacy of the treatment and the
rate of adherence to the treatment (Epstein & Cluss 1982). Adherence to this demanding and
time consuming regimen while keeping up with education, work and a social life is extremely
difficult. The issue of adherence to prescribed treatments such as pancreatic enzyme therapy
is   of   concern   to   health   professionals.   Despite   the   rationale   for   pancreatic   enzyme
replacement therapy, many patients do not take their supplements optimally. Very little is
known about the relationship between what patients tell us and what they actually do with
regards to their enzyme therapy. It is not clear to what extent patients follow the dietitian’s
advice regarding optimal pancreatic enzyme use. To provide realistic and individualized
patient care, an appreciation of the reasons for, and the extent of non-adherence are
required. Despite regular dietetic advice there is a sense that some patients do not manage
their PERT effectively. Should this be accepted as something that we cannot do anything
about or does it require further exploration? There is very little guidance available for
dietitians on how to deal with this type of situation despite the fact that these patients typically
present as failing to gain weight despite long-term use of nutritional supplements. 
Haynes (1979) defines compliance as, “the extent to which a person’s behaviour (in terms of
taking medications, following diets, or executing lifestyle changes) coincides with medical or
23health advice”. The term compliance is used in much of the earlier literature to describe the
process of giving advice. This has largely been replaced by adherence to imply a more active
role for patients. Adherence is a complex behaviour often influenced by the patients’
perceptions and expectations. The term adherence and compliance are used interchangeably
within studies and this is reflected within the context of this review. 
Schwartz et al (1962) attempted to classify non-compliance into five groups – errors of
omission, of purpose (taking medication for the wrong reason), of dosage (more, less), of
timing or sequence, and taking potentially interactive medications not prescribed by the
doctor. Koocher et al (1990) outlined a typology of non-adherence for CF patients, in whom
three types are described: those who have inadequate knowledge, those who present
psychosocial resistance, and those who are educated non-adherent, that is, have made an
informed choice not to adhere. Bryan Lask (1994), professor of child and adolescent
psychiatry, followed on from this by suggesting that CF patients could be described as fully
adherent, partially adherent or non-adherent. Lask classified non-adherence as ‘refusers’ who
say they don’t want or need a particular treatment; ‘procrastinators’ who are likely to say they
will adhere more in future but never seem to get around to it; and ‘deniers’ who will not admit
to any non-adherence even when it is quite clear that their adherence is poor.  
1.5.1 How can adherence be measured in CF?
It is important to determine the precise definition of adherence used for a particular study.
The majority of work studying adherence are descriptive studies, making comparisons
between adherent and non-adherent patient groups. However, because of the numerous
regimens required in cystic fibrosis, defining a patient as either being ‘adherent’ or ‘non-
adherent’ may depend on a particular treatment or a specific stage in the patient’s life.
Methods include the measure of actual adherence rates; number of treatments taken divided
by the number prescribed or against a predetermined standard or recommendation. 
There are direct and indirect measures of adherence. Indirect methods include pill counts,
mechanical devices, physician estimates of compliance and self-reporting methods (e.g.
questionnaires, interviews). These are generally not costly or time consuming but are subject
to inaccuracy. More objective and direct methods include blood and urine assays which may
be more accurate but are often expensive, unavailable, or simply unreliable in long-term
assessment (Epstein & Cluss 1982).
24Self-reported questionnaires (also referred to as psychometric tools), have also been used to
measure adherence. Examples include the ‘Medical Compliance Incomplete Stories Test’ (M-
CIST) and the ‘Manchester Adult Cystic Fibrosis Compliance questionnaire’. The latter was
developed to measure the rates of adherence to treatments and medical advice, the reasons
for non-adherence and the patients’ perception of their level of adherence (Abbott & Gee
1998). M-CIST was developed by Czajkowski & Koocher (1987) and is a tool based on a
competency / coping skills model, predicting medical compliance of adolescents with CF. It
comprises of five incomplete stories in which the main character is confronted with a
dilemma. The patient is asked to complete the story and predict the outcome for the
character.  It  has been  described to  discriminate  between   adherent  and  non-adherent
patients. 
Physician estimates of non-adherence have been used in many studies. Roth & Caron (1978)
found that physicians’ judgments were significantly better than chance but nethertheless low
in accuracy when estimating adherence to antacid therapy. They also found that physicians’
accuracy did not improve with increasing familiarity with the patient. A review by Murri et al
(2002) of studies in HIV-infected people also found that physicians often render informal
assessments of adherence but they were often inaccurate. These predictions were found to
play a crucial role in determining the timing for initiating anti-retroviral therapy. In contrast to
these findings, Abbott et al (1994) found that both the physician and physiotherapist
differentiated   between   adherent   and   non-adherent   CF   patients   for   exercise   and
physiotherapy in most cases. An explanation for this difference could be that non-adherence
is easier to recognise for CF clinicians who often establish long working relationships with
patients. 
This literature review revealed a total of 11 papers measuring treatment adherence specific to
CF, 5 of which focus on adults whilst 2 include young adults along side children. A variety of
data collection methods have been used including interviews, questionnaires, scales, case
illustrations, and critical incidents/narratives. However, only one uses direct measures using
urine analysis (Meyers et al 1975) and this measured only the adherence to antibiotics. 
1.5.3 To what extent is adherence a problem in CF?
Adherence to medical advice and treatment is a recognized problem in all illness states.
Patients prescribed long-term medication regimens for prophylaxis or for chronic diseases
appear to be less compliant to those on short-term regimens (Epstein & Cluss 1982, Sackett
and Snow 1979).
25The extent to which non-adherence exists within cystic fibrosis is an area of debate. The
literature suggests that patients with CF are a generally adherent group with respect to
treatment (Gudas et al 1991, Meyers et al 1975, Passero et al 1981) but others have found it
to be a severe problem (Schwartz et al 1962, Strausse & Wellisch 1981). Possible reasons
for this may be due to differences in experimental design, including how the variables have
been measured and the methods used. Table 1.2 shows how adherence to pancreatic
enzyme taking and exercise was greater than the reported adherence to physiotherapy and
vitamin supplements (Abbott et al 1994), suggesting that patients use their immediate
symptoms to gage the priority of treatment. Patients may be focusing on the short term rather
than the long-term benefits of treatment. 
Table 1.1: Comparison of adherence rates to therapy regimens 
Authors No Age Method PERT Antibiotics CPT Diet Vitamins
Conway et al
1996
80 14-40 yrs Questionnaire 85% 83% 41% 50% n/a
Abbott et al 1994 66 16-44 yrs Questionnaire 83% n/a 53% 53% 46%
Passero et al
1981
58 children
& adults 
Retrospective
reports &
interview
n/a 93% 40% 20% 90%
Meyers et al
1975
61 children Urine analysis
&  attitude
survey
n/a 80% n/a n/a n/a
n/a – not assessed
CPT – chest physiotherapy
Meyers et al (1975) found that 80 per cent of their CF clinic population adhered completely
with prescribed antibiotics, as detected by urine samples containing antibacterial activity.
Gudas et al 1991 did similar work on perceived compliance with prescribed treatment.
However, the results are not available as a percentage for easy comparison. Instead a 0 to 4
point rating scale was used, with 4 representing full compliance. Medication scored highest
with a mean of 3.52, followed by diet (mean 2.85) and CPT (mean 2.58). It was unfortunate
that the medication category grouped together compliance with antibiotics, PERT, vitamins
and other prescribed drugs and then an average was produced. As demonstrated in the table
above, patients vary greatly in their adherence to each of these therapies so it does not
inform about individual therapies. 
26The two most recent studies (Conway et al 1996 and Abbott et al 1994) show similar
adherence rates for PERT, CPT and dietary therapy. The study by Abbott gives an insight
into how well patients take their enzymes and provides explanations for poor adherence.
Eighty-five per cent (n=51) always took enzymes with main meals, 12 per cent (n=7) usually
did, and 3 per cent (n=2) occasionally adhered with the treatment regimen. Adherence to
enzymes was poor with snacks; only 22 per cent always took enzymes with snack, 45 per
cent usually did, 23 per cent occasionally did and 10 per cent never did. 
Although PERT adherence rates generally came out well in comparison to other treatments, it
raises the question as to whether this is a realistic and acceptable level or whether we should
be making efforts to improve this. Table 2 demonstrates that approximately 15 per cent of
patients are non-adherent but the studies show no indication about the type of patient this is.
We need to understand whether patients poorly adhere because they suffer no adverse
consequences or if these are patients who continuously struggle being underweight and are
relying   on   expensive   nutritional   supplements   unnecessarily.   It   could   be   argued   that
adherence is more crucial in those patients who fail to gain weight despite intervention, suffer
from   symptoms   of   maldigestion,   are   high   lipase   users   and   require   referral   to   a
gastroenterologist for further investigations. 
1.5.4 What are the consequences of poor adherence?
Non-adherence has been described as a serious healthcare concern, contributing to the
increasing cost of health care. Medication used incorrectly or not taken at all, can impact on
the healthcare providers’ time, effort, and expertise. Poor adherence to PERT can mislead
clinicians to believe that the therapy is ineffective, leading to an unnecessary dose increase or
adding in another drug such as adjunct therapy to improve efficiency. Medications and their
correct use are considered among the most valuable and cost-effective components of acute
and chronic medical management of disease. In the US, inappropriate drug use accounts for
ten percent of the nation’s hospitalisation with  the cost  of medication non-compliance
estimated to be $100 billion annually (McLeod et al 1993).
The UK CF population is comparatively small compared to other chronic diseases, which
perhaps explain why the health and financial costs of PERT non-adherence has yet to be
examined. However, it would be inappropriate to conclude that better adherence has no
effect on clinical outcome, particularly due to the complexity of measuring health outcomes. It
is commonly assumed that the consequences of poor adherence to CF treatment are
27infective exacerbations, disease progression, costs of wasted drugs, increased visits and
hospital admissions (Abbott et al 1996). 
Omission, inadequate and untimely dosages of PERT is considered to impair the digestion
and absorption of food. This will then impact on the patient’s ability to maintain an ideal
weight and, as mentioned earlier, a low BMI compromises lung function. Accelerated loss of
respiratory function and more frequent infective exacerbations may result in increased
outpatient visits and hospital admissions and consequently time off from work or college.
Unnecessary prescriptions may be occurring if dosages vary from the patient’s actual use
wasting resources and incurring extra costs.
When assessing patients it is difficult to know whether repeated reports of GI symptoms are
due   to   poor   adherence,   inadequate   /   excessive   enzyme   use   or   a   more   serious   GI
complication.  Studies designed to improve  adherence therefore cannot  guarantee that
patients will achieve control of their symptoms and disease. Patients who are prescribed a
therapeutic regimen and improve are often believed to be compliant and ones who do not
improve are thought to be noncompliant (Epstein & Cluss 1982). These authors also suggest
that ‘adequate’ as opposed to ‘very high’ levels of patient compliance might be suitable
treatment objective because strict adherence to therapeutic regimens may not always
produce positive medical outcomes. 
A 100 per cent adherence rate cannot prevent the patient with CF dying prematurely, which
raises the dilemma as to whether complete adherence to enzyme therapy is necessary and
whether it makes a difference. It is difficult to provide patients with the minimum amount of
treatment needed to maintain health, as this could be perceived as unethical. There are
aspects of CF therapy which are only offered to patients who clinicians presume comply, due
to hospital budgets and the increased need to show cost effectiveness (e.g. TOBI and
Dornase). 
1.5.5 Are older patients and those with more severe CF more likely to adhere to
treatment? 
The vast majority of early research has focused on children whose parents are generally
responsible for implementing medical recommendations (Strauss & Wellisch 1981). Other
studies have combined children and adults (Meyers et al 1975, Passero et al 1981). Now that
increasing numbers of patients are reaching adulthood, there is more interest in how the adult
28population deals with their disease (Abbott et al 1994, Conway et al 1996, Czajkowski &
Koocher 1987). 
Significant issues exist for different age groups and the time patients have had to deal with
their   disease.  Studies  have   shown   adolescence  to   be   the  most   challenging   time  for
adherence but there is no evidence to suggest that older patients with CF are more likely to
adhere based upon the assumption of increased maturity and responsibility. A reality of CF is
that older, and often sicker, patients are generally prescribed more types and doses of
medications. Some older patients require 80 to  100 pills per day, a frustrating, time
consuming and continuous reminder of their disease (Gudas et al 1991). 
1.6 FACTORS INFLUENCING ADHERENCE TO CF TREATMENT 
In order to improve rates of adherence, factors which predict barriers to change need to be
identified. Exploring the underlying reasons for poor adherence can help provide a clearer
understanding for individual differences. 
1.6.1 Symptoms 
Abbott et al (1994), showed that the lowest adherence rates occurred when there was no
immediate   risk   or   discomfort   associated   with   not   complying   with   the   treatment   (e.g.
physiotherapy and vitamin therapy), whereas, adherence improved when the treatment
provided immediate benefits (e.g. enzymes to avoid steatorrhoea).  Similarly Conway et al
(1996) saw that compliance with individual treatments varied according to their perceived
unpleasantness and degree of infringement on daily activities. This suggests that patients
may use their immediate symptoms to decide when to discontinue and continue treatment. As
a result, patients may be focusing on the short term rather than long-term benefits of
treatments. It has been suggested that the treatment regimens may eventually become too
arduous to maintain (Czajkowski & Koocher 1987).  
1.6.2 Variables 
Demographic variables (age, sex, knowledge of disease, employment status) and clinical
factors (disease severity, age at diagnosis, frequency of clinical visits) have been evaluated
as possible predictors of adherence in CF with equivocal results. Gudas et al (1991) found
that younger children showed greater perceived adherence.  Females have been shown to be
less adherent in one study (Czajkowski & Koocher 1987) but the same as males in others
(Gudas et al 1991, Meyers et al 1975, Abbott et al 1994). No association has been found
between employment status or age at diagnosis. Socioeconomic factors appear to be
important, with the lower the socioeconomic level, the lower the compliance (Gudas et al
291991). Higher levels of perceived compliance with CF treatment were found to be associated
with less satisfactory marital relationships and with less frequent social contacts (Geiss et al
1992). This could be attributed to either the complex and time consuming regimens being
detrimental to social and family relations or that when marital satisfaction and social contact
are lower patients become more involved with their care and therefore more compliant.
Czajowski & Koocher (1987) found that non-adherence rates increased with the number of
hospitalizations and days missed from school or work by the patient 
1.6.3 Inadequate knowledge and understanding
Koocher et al (1990) reported that non-adherence seems to be related chiefly to a lack of
information or inadequate understanding of information that is available. These are different
issues but because they are difficult to determine there is a tendency for this to be overlooked
during the time constraints of clinic. 
Ievers et al (1999) looked at adherence and knowledge of prescribed treatments. Findings
showed that both the child’s and parents’ recollections of the prescribed treatment differed
from the physician’s. Only around half of the children were able to accurately describe the
frequency and duration of their treatment. Studies have shown higher levels of medication
and CPT adherence in children with increased knowledge of illness (Gudas et al 1991).
Educational approaches have attempted to address the problem of adherence by promoting
knowledge about the reasons for treatments and therapies. Inadequate knowledge about
PERT treatment may result in unintentional poor adherence to therapy. Conway et al (1996)
found that 19% of patients were unaware that abdominal distention and pain are associated
with inadequate PERT. 
Modi & Quittner (2006), identified substantial gaps in nutritional knowledge for children with
CF and their parents attending CF clinic in Florida. They lacked knowledge about the
importance of adding snacks and boosting calories, and 26% were unaware that enzymes
should be taken before a meal and snack. The vast majority of parents (92%) were unaware
that fat has more calories than carbohydrates and proteins, and 19% were unaware that
children with CF need 125-150% of the recommended daily allowance of calories.
A South African study by Henley & Hill (1990) looked at the knowledge of CF patients
(age>12years) and their families and found that:
30• 13% of mothers and 11% of patients failed to recognize that oily and smelly stools are
due to fat malabsorption. 
• 30% of parents and 17% of patients failed to link the dosage of pancreatic enzymes to
the amount of fat in the diet.
• 20%   of   mothers   and   11%   of   patients   believed   that   pancreatic   enzyme
supplementation is necessary only with main meals and that they should be taken
after meals.
Although the above study showed problems in relatively few cases, it remains a concern as
teaching patients and families on treatments such as dietary adjustment and enzyme
administration has long since been an essential component of treatment. In the absence of
clinical investigations for maldigestion, we rely heavily on patient’s ability to report adverse
symptoms. PERT is such a huge part of patients daily lives that it is rudimentary that we get
these principles right. Without accurate information on what the patient is or is not doing,
future management may be ineffective. Examples of this include unnecessarily starting
adjunct therapy, increasing PERT and commencing nutritional supplements/enteral feeding.
We assume patients are knowledgeable on transfer to the adult service because they have
had   regular   dietetic   input   since   diagnosis.   Patients   may   however   have   forgotten   or
misconstrued information or developed problematic behaviours. In addition it may be the
parents who have been taught the relevant information, and patients gain independence and
move away from home the support and guidance diminishes. 
There are many educational models to assist patient knowledge and understanding although
this has mainly been used within the clinical areas of eating disorders and obesity and more
recently, diabetes. There is limited research on patient knowledge within the adult population
as work has mainly focused on child and parental understanding (Conway et al 1996, Henley
& Hill 1990). It remains unclear how much our patients know about their CF and for those
wanting to know more, where they go for answers. Patients may have a limited understanding
of their disease and the implications for treatment. We perhaps underestimate how daunting
the consultation process is for patients or that they may be too embarrassed to ask what what
they should know? Anxiety surrounding their health combined with the bombardment of
information by different clinicians is likely to make it difficult for patients to retain all the advice
that is offered to them.
311.6.4 Communication
Insufficient knowledge and misconceptions surrounding treatment may also be attributed to
poor communication between the patient and health professional. Studies have demonstrated
that satisfied patients are more likely to comply. In a review of 21 studies of hospital patients,
41 per cent of patients were dissatisfied with their treatment (Ley 1988). Related factors
include poor transmission of information from patient-to-doctor, low understandability of
communications addressed to the patient, and low levels of recall of information by patients
(Ley 1982). This study showed that levels of satisfaction stem from various components of
the consultation, including the emotional support, the behavioural aspects (e.g. prescribing,
adequate explanation) and the competence (e.g. appropriateness of referral, diagnosis) of the
health professional (Ogden 1996). 
An early study on compliance by Hulka et al (1976) described how the drug dispensing and
consumption process are intimately involved with human factors, such as the prescribing
practices of the physician and the memory and motivation of the patient. The study focused
on   the   impact   of   doctor-patient   communication   in   affecting   patient   medication-taking
behaviour and physician awareness of these behaviours. Increasing the number of drugs
prescribed and the greater the complexity of scheduling within the medication regimen, were
associated with increased errors.  Modi & Quittner (2006) also found that regimen complexity
influenced practice, with fewer treatments associated with better rates of adherence for both
CF and asthma.
1.6.5 Behaviour and barriers to adherence
Behaviour is what we believe and how we feel. It is a combination of knowledge, practices,
and attitudes. If we want to change behaviour then we need to change the underlying beliefs
and feelings to that behaviour. Many factors influence whether we achieve behaviour change
in a health context i.e. motivation, beliefs, values, perceived costs and benefits, barriers and
support. People’s beliefs are not based simply on what they are told to believe. (Adapted from
Stainton Rogers et al 1996). 
A recent study by Modi & Quittner (2006) studies barriers to adherence in children with CF
and shows a very different picture to that detailed above. Seventy-seven percent of parents of
children with CF endorsed barriers for enzymes, 92% for airway clearance, 69% for nutrition,
and 73% for nebulized medications. Fifty percent of children with CF endorsed barriers for
enzymes, 75% for airway clearance, 44% nutrition, and 75% for nebulized medications.
32Studies identified forgetfulness (Conway et al, 1996; Borrowitz et al, 1994; Modi & Quittner
2006,   Abbot   et   al   1994),   difficulties   with   time   management   (Modi   &   Quittner   2006),
embarrassment (Abbott et al 1994), and difficulty swallowing pills (Modi & Quittner 2006) as
the most significant barriers to treatment in CF. In a study specifically interested in vitamin
therapy, reasons cited for not taking vitamin therapy included ‘I don’t think I need them’, ‘they
aren’t as important as my other medications’; ‘I am already taking too many pills’ (Borowitz et
al 1994). Other reasons include uncertainty as to why they should take them and the
commitment and time demanded by the treatment regimen. Although these factors have been
suggested as barriers to optimal CF treatment, they provide a limited insight into the
problems specific to PERT.
Although research on CF has predominantly emphasized the medical management of the
disease, the psychosocial aspects also require consideration. Since the 1990s there has
been greater emphasis on the psychosocial burdens of this disease. Patients with CF have
many complex and unique social and psychological problems, and their chronic illness can
impact greatly on all aspects of their daily lives. Patients’ attitude and beliefs towards their CF
may have a significant effect on their adherence to treatment. Research into this area has
however shown that young adults with CF had an age-adequate psychological functioning
(Moise et al, 1987) and relatively good psychosocial health (Shepherd et al 1990). 
Theoretical models have been applied to understand treatment adherence in patients with CF
and other chronic diseases. The Health Belief Model (Becker 1974; cited in Ogden 1996) was
developed to predict preventative health behaviours and also the behavioural response to
treatment in acutely and chronically ill patients. It assumes that health promoting behaviour
such as adherence, are determined by the patients perceived seriousness of the illness and
the  perceived  effectiveness of   the  treatment.   Patients  who   do  not   underestimate   the
seriousness of their illness have been shown to be more compliant (Czajkowski & Koocher
1987). Patients appear to underestimate the severity of their disease and their perceptions
remain constant over time even when their health is clinically deteriorating (Abbott et al
1995). This may become harmful if it diminishes adherence to treatment regimens.  However,
Abbott et al showed that patients adherent to these regimens had greater external control
beliefs (chance factors, health professionals and family) than those who were non-adherent.
Those with minimal disease were more likely to adhere to multivitamin therapy than those
with more pulmonary involvement (Borowitz et al 1994). 
33Two styles of coping have been identified through research – hopefulness (optimistic,
determined and positive way of acting, thinking and feeling) and resignation (avoidant,
passive and helpless way). Greater optimism was associated with increased adherence to
medication and physiotherapy in children and adults (Gudas et al 1991). Czajkowski &
Koocher (1987) also support the need for an optimistic outlook and that patients who believe
their actions make a difference will be more likely to take the necessary steps to deal more
adaptively with their lives. It is also possible that those who believe they have control over
their CF may make a rationale decision not to adhere to all their treatment, enabling a
balance between treatment regimens and life quality (Abbott & Gee 1998).
Denial or underestimation of the seriousness of their disease may afford emotional protection
to the patient (Abbott et al 1995). Moise et al 1987 noted higher self-esteem, lower levels of
psychological distress, and better adaption in patients who used avoidant coping strategies
than in those who used more direct and positive coping methods. Strauss & Wellisch (1980)
found that a denial of illness-related problems is a useful coping strategy. Young adults with
CF who reported a repressive or avoidant coping style had more positive psychological
adaption (Moise et al 1987). In chronic illness, these coping mechanisms can distract the
need for optimal treatment. Interestingly disease severity was not related to these findings.
Discrepancies may occur due to physicians deciding to withhold information to allow the
patient to maintain hope, representing instances of unintentional incomplete communication.
While likely to be due to the patient’s defensiveness and denial, this could also be a function
of the doctor’s own discomfort with chronic and fatal illness (Strauss & Wellisch 1980).
1.7 GIVING ADVICE AND ITS LIMITATIONS 
Our   aim   is   to   provide   patients   with   evidence-based   recommendations,   however   it   is
meaningless if there is miscommunication from the dietitian and misuse of prescribed
medication by the patient. In contrast, many patients appear not to heed the advice given,
however clearly the dietitian thinks she is putting it across. There are also many times when it
seems that the patient’s difficulties are not diet related (Gable 1997). 
Dietitians have traditionally functioned as nutritional advice givers rather than behaviour
change agents (Rapoport & Nicholson 2000). Negative responses to advice such as non-
adherence can leave the dietitian feeling frustrated that patients haven’t acted upon their
advice. The difficulty for health professionals lies in acknowledging that we may or may not
34play some role in patient’s ability to take their treatment. Until recently it was assumed that if
patients were informed about the risks associated with negative behaviour this would be
sufficient for them to change. However, choosing to change one’s diet is guided by a complex
interaction of psychological factors (Brownell & Cohen 1995). A number of psychological
models have been used to explain and predict changes in health behaviour. This includes the
Health Belief model, the use of health locus of control, a self-efficacy model / social learning
theory (Bandura), a model emphasizing Stages of Change (Prochaska & DiClimente), and a
behavioural intention model. 
Since the late 1980s there has been a growing interest in using educational approaches in
dietetic practice. Counseling as part of the dietary process started to be seen as an important
training issue for dietitians. The following statement summarises this:
‘Effective communication is central to the existence and performance of any dietitian.
How this communication is delivered is therefore of vital importance, not only to the
individual receiving the advice but also to the dietitian. Using background knowledge,
dietitians aim to employ their skills to ensure that some form of dietary modification,
no matter how small, has been negotiated within the consultation for the wellbeing of
the individual. Skills indeed when any adjustment in food intake also includes
changes in other aspects of someone’s lifestyle’
Jane Eaton, Honorary Chairman of the BDA 1995-97
Taken from Counselling Skills for Dietitians, Gable 1997
Key features would include using reinforcement, giving feedback, offering an opportunity for
individualization, facilitating behaviour change through use of skills, resources and education
being relevant to the patient’s needs and abilities (Parkin 2001). However, a study of 394
dietitians showed respondents felt that they had not received adequate training in behaviour
change skills in their dietetic training. Certain key areas were perceived as particularly
deficient,   notably   the   application   of   cognitive   behavioural   therapy   (CBT),   motivational
techniques and relapse prevention (Rapoport & Nicholson 2000). A possible reason for this is
that dietitians have learnt the theoretical knowledge during their training but in view of the
numerous models that exist, assistance is required to apply them at a practical level so that
they are relevant to a particular area of expertise. Dietitians typically apply behavioural
techniques for dietary change in obesity, diabetes and eating disorders but may feel less
confident applying this to other clinical area of dietetics. 
35Individuals with CF do occasionally express their concerns to members of the team, usually
when the burden becomes too much and they are having difficulties coping. We do not tend
to routinely ask what patients think and worry about probably because we feel inexperienced
to deal with problems. When determinants of non-adherence are identified by the patient, we
need strategies for intervention. Education alone no longer seems conducive to bring about
change in behaviour and there is the belief that psychological issues should be incorporated
into clinical practice to ‘normalise’ problems before they become a big issue. No evidence
could   be   found   of   these   methods   being   used   by   dietitians   working   in   CF   but
psychoeducational approaches have been successful in other clinical areas. 
Preventative   programmes   directed   towards   self-management   of   asthma   have   shown
improved adjustment, increased medication compliance, greater perceived self-competence
in managing symptoms, and decreased use of medical services (Lehrer & Hochron 1992).
Behavioural studies have been successful in increasing calorie intake in children. Jelalian et
al (1998) conducted a meta analysis which showed that behavioural intervention produces
weight gain that is comparable to medical intervention (oral supplements, enteral nutrition and
parenteral nutrition)
Motivational interviewing (MI) techniques, previously used for addiction councelling, have
been used by dietitians in several studies. Mhurchu et al 1998 performed a randomized
controlled trial completed by 97 patients, comparing MI with standard dietary advice for
hyperlipidaemia. The motivational interviews contained more reflecting, exploring and non-
judgmental giving of information. Despite the MI consultations being longer than the standard
interview, it was no more effective. MI was more successful for increasing fruit and vegetable
consumption than standard nutritional education (Resicow et al 2001). However the MI group
was more intensive, requiring more sessions. 
1.7.1 Concordance
In 1997 the term concordance was introduced by the Royal Pharmaceutical society (Maniker,
Briten, Feely, George, 1997). Concordance is used to describe the process of a consultation
where the decisions are in concordance with the wishes of doctor and patient. It is proposed
as the new term to replace both compliance and adherence. Whereas it is possible to have a
non-compliant   patient,   it   is   not   possible   to   have   a   non-concordant   patient   because
concordance refers to the discussion process and not to patient behaviour (Weiss, 2003).
36The Department of Health endorsed the concept of concordance by setting up the medicines
partnership along with its website (www.medicines-partnership.org). 
The concept of concordance has been criticised and almost ten years on, there is still a
tendency for health professionals to use the term adherence rather than concordance.
Concordance is fine in theory but is mostly not being practised (Jones et al 2003). This is the
case with our service and part of what we do is based on concordance. I would agree that
there is more chance of enlisting patients who are co-operative, yet it is also an idealistic way
of looking at this approach, as time restraints in the clinic environment cannot always allow an
extensive consultation. Heath (2003) states that the problem is that concordance is the wrong
term because it exaggerates the potential for concordance between the aspirations of
medical science and those of individual patients striving to make the best of complicated and
challenging lives. 
Professionalism   promotes   evidence-based   practice   but   this   can   conflict   with   patient
autonomy. If the only treatment the patient will agree falls substantially short of what modern
medicine can achieve the doctor may be left with a burden of responsibility that is hard to
manage emotionally, ethically and legally (Marinker & Shaw 2003).
1.8 SUMMARY OF LITERATURE AND AIMS OF RESEARCH
As yet, no consistent single reason or set of predictor variables has emerged to explain why
patients engage in adherent or non-adherent behaviours (Abbott & Gee 1998). It is assumed
that   improving   adherence   to   treatment   would   improve   symptom   control   and   disease
prognosis but as yet there is no conclusive data to substantiate this. 
Patients vary in their degree of pancreatic insufficiency and also, in their reported symptoms.
Patients who are adherent to their PERT may remain symptomatic whereas patients who are
not adherent may remain asymptomatic. It must therefore be considered that whilst outcome
and adherence are related, they cannot be guaranteed. CF patients commonly exhibit
abdominal pain,  loose  stools and  weight   loss.  This could potentially  be  due to  poor
adherence, limited understanding or other factors. Many patients do not willingly disclose the
problems they are experiencing and when the prescription of PERT doesn’t produce the
expected benefit the dose is changed for an alternative, rather than considering adherence. 
37There is also the question as to what is considered an acceptable adherence rate for a given
treatment. Adherence measures need to be realistic and related to the minimally acceptable
therapeutic dose required to produce the desired outcome. For PERT, this needs to be
assessed individually as the dose is adjusted according to diet and degree of pancreatic
insufficiency.   It   is   unknown   whether   small   discrepancies   in   PERT   use   have   clinical
significance. There is therefore a need for further development and validation of adherence
methods and tools such as questionnaires for both children and adults with CF. It is important
to understand adherence behaviours over time and to recognise the specific times during the
patients life when a higher level of adherence is more difficult to accomplish (Abbott & Gee
1998). 
There are few valid and reliable objective measures for adherence in cystic fibrosis. The
inconsistent findings reported in the literature regarding predictors of adherence behaviour
are likely to be a product of the medley of methodologies employed (Abbott et al 1998). When
discussing this patient’s care, there is a tendency for the multidisciplinary team to make
assumptions as to whether patients are adhering to their treatment. An example of this is
when completing the paperwork for the national CF database as it asks to classify the patient
as adherent, partially adherent or non-adherent. In some instances this is straightforward due
to the patient openly acknowledging non-adherence, however in most cases it is largely
based upon assumption. The accuracy of clinician’s predictions of adherence showed some
success in a study on CF patients. Yet to be investigated is whether incorrect or negative
assumptions inadvertently influence the consultation process. 
Non-compliance may be intentional or involuntary. It may relate to the quality of information
given, the impact of the regimen on daily life, the physical or mental incapacity of patients, or
their social isolation (Marinker & Shaw 2003). Current methods of improving medication
adherence  for chronic  health problems are mostly complex,  labour   intensive  and  not
predictably effective (McDonald et al 2002).
An area that is often overlooked is when a patient makes an informed decision to not follow
advice, despite having an understanding for the reasons for the recommended therapy. A
patient may have weighed up the perceived costs versus perceived benefits. The published
literature evaluating the extent to which behaviour limits PERT is limited. There is little point in
intense treatment regimens aimed at increasing life expectancy if it compromises quality of
life. When considering patient treatment we need to adopt a more holistic approach and
38consider the social and psychological aspects of a patient’s condition. The ethical problem is
further complicated by the findings that healthcare professionals do not always themselves
comply with the best available recommendations about health, even when issuing advice to
patients (Ley 1982).
1.9 CONCLUSION
In conclusion, our present understanding of how optimally patients manage their enzyme
therapy and their perceptions of this particular treatment is constrained. The literature has
shown that forgetting and embarrassment are well known problems associated with non-
adherence to the CF treatment regimen. However there is limited focus specifically on
enzyme management. Studies have tended to investigate a selection of therapies together
such as physiotherapy, vitamins, antibiotics and enzymes and then compared and contrasted
between them. As adherence to PERT came out more favorably than other therapies, these
studies did not address strategies for dealing with non-adherence to enzyme therapy. Dietetic
research has focused on the areas of education (McCabe 1996, Basketter et al 2000,
Stapleton et al 2000) and reducing patients down to below the CSM recommendations of
10,000 U lipase per kg/ day (Beckles Willson et al 1998, Lowdon et al 1998). A lack of
consensus exists amongst health professionals regarding PERT administration. This is likely
to be due to a lack of objective tests, CF physician’s being specialists in respiratory rather
than gastrointestinal management and increased responsibility on dietitians in the unfamiliar
territory of advising on drug therapy. 
In order to improve the efficacy of advice, treatments and clinical outcomes we need a better
understanding of the basis for poor adherence. The use of PERT in patients with CF remains
ambiguous as it is unclear how optimally patients take their enzyme treatment in respects to
quantity, frequency and timing. In order to enhance clinical care we need to be more informed
about the prevalence, extent and determinants of poor adherence within our service. 
Little consideration has been given on ways to improve adherence within standards of
practice. This is made more difficult by the lack of guidance for dietitians involved in the
prescribing of enzymes. Particularly difficult issues include dealing with patients who exceed
the CSM recommendations, identifying and advising patients who are non-adherent, and the
availability of accurate laboratory tests to monitor maldigestion. 
It is clear from the literature that there is a need to address a number of issues in order to
establish a conceptual framework for prescribing, educating and monitoring enzyme use.
39However the skill base of the dietitian is not behavioural so communication skills are limited to
traditional advice giving rather than problem solving. Better understanding of these issues will
provide assurance that the current management is working, or identify inadequacies which
will require further attention. However, realising the work that has been done in other clinical
areas has been positive. There is growing evidence that for patients receiving long-term
advice at regular intervals, there is a need for more effective and innovative styles of
providing   advice   on   treatment   regimens.   Applying   these   principles   to   CF   may   help
investigating how other chronic diseases deal with these issues. 
RESEACH QUESTIONS
Specific areas where we need more information are: 
This project will firstly address whether patients take their PERT in accordance with clinical
recommendations. All therapies are dependent on patients taking their treatment effectively
therefore the first line for investigation is based on the practicalities of enzyme management.
For a small proportion of patient’s, swallowing medication can be problematic. Some patients
request liquid or effervescent preparations of medication such as vitamins, which suggests
that taking PERT, may also be a challenge for patients. We are currently not aware of any
patients in our population reporting this problem but it has occurred in the past and has meant
that patients split open their PERT and add the microspheres to food. It is recommended that
enzyme capsules are taken intact as the enteric coating protects the contents from acid
damage.
It is unclear how precisely patients take their PERT (i.e. whether they count or estimate their
dose). PERT administration requires an element of patient self-titration in accordance to the
fat content and quantity of food and drink consumed. Patient’s typical enzymes doses are
assessed and monitored by the CF dietitian. Despite this being a frequent question asked
during the clinical consultation, patients can often be vague about how many PERT they take.
In view of the fact that many patients take a considerable number of capsules per meal and
snack, patients have been known to take an estimated amount or handful of enzyme
capsules from the pot to save time counting them out.
The literature review outlined the CSM recommendations to not exceed 10,000 U lipase/kg.
We are aware that many of our patients exceed this. We wanted to know what characteristics
were associated with high lipase doses. Are these recommendations realistic?
40Patients are recommended to titrate their PERT in accordance to the fat content of food and
drink but it is unclear how well this is practically managed.
The second area of interest is to determine the prevalence of non-adherence to PERT in our
adult patients. We currently have no way of knowing how frequently patients miss taking their
enzymes with meals and snacks. This is a fundamental requirement; if no problems are
identified then what we are doing is working. However, it is expected that as found in previous
studies, that taking enzymes with food, particularly snacks is problematic. 
Thirdly, to identify the constraints associated with PERT use. There is limited work in this
area and it is hoped that more could be learnt on the difficulties experienced by patients in the
day to day management of their enzyme therapy.
Finally, categorizing patients as being adherent or non-adherent tends to occur between
clinicians so it would be interesting to determine the accuracy of our assumptions. If the data
is able to distinguish adherers from non-adherers, this could be compared with clinician’s
predictions. There has been some success in previous CF studies of clinicians predicting
non-adherence. 
1.10 AIMS OF RESEARCH
Substantive hypotheses
It is hypothesised that it is possible to identify specific factors that determine behaviour to
pancreatic enzyme replacement therapy in patients with cystic fibrosis. If these issues were
addressed patient management could be improved.
Whilst giving advice works for some patients, for other knowledge is not enough. It has been
important to assess the prevalence of non-adherence to PERT in order to determine the
characteristics   of   patients   at   risk   and   to   improve   clinical   practice.   This   project   has
acknowledged the practical aspects of taking PERT as well as the patient’s attitudes and
beliefs surrounding their therapy which were previously misunderstood.
Aim of the research
1) To describe attitudes of patients with cystic fibrosis to pancreatic enzyme replacement
therapy.
412) To determine the extent to which education, beliefs and circumstances limit optimal PERT
practice.
3) If so, to consider what measures might be taken to remove these barriers to lessen the
impact of such behaviours.
Objectives
This study has been designed to provide evidence based research data to support or refute
the conventional approaches to providing advice to patients on their pancreatic enzyme
therapy. The framework that will be generated as a result of this research will be the basis to
facilitate and refine the communication process in the routine nutritional review of cystic
fibrosis patient. Specific objectives are:
1) To administer questionnaire during the routine review of patients during their outpatient
clinic appointment.
2) To measure enzyme usage and rates of adherence (i.e. preparation, dose, and frequency).
3) To collect data on the attitudinal variables (i.e. adherence, behaviour).
4) To analyse the data and use it to test the hypotheses described in the aims. 
5) To make recommendations about the factors which have been shown through the study to
affect attitudes to pancreatic enzyme and the influence of this on adherence.
42CHAPTER 2: METHODOLOGY
2.1 OVERVIEW OF RESEARCH DESIGN AND METHOD
The overall structure of the research is of a descriptive study with the target population being
adult patients with cystic fibrosis. This project used a survey method in the form of a
questionnaire, which was specifically designed to collect data on practice, beliefs and
circumstances relating to enzyme use and the difficulties experienced with this type of
therapy. This chapter includes details of this approach, description of the population, project
questions, ethical considerations and statistical methods.
A confidential and anonymous questionnaire gives patients the opportunity to express the
realities of taking their enzyme therapy and the problems experienced. Getting answers to
these questions could potentially improve the dietetic consultation and help overcome
barriers to behaviour change. The purpose of this is to yield patient data such as patient’s
behaviours that otherwise would not be possible due to the structure and time-restraints of
the routine dietetic assessment. Using this questionnaire during the clinic environment, if
successful, may become a routine part of patient assessment.
The data obtained will promote a greater awareness and appreciation of patient’s perceptions
of the enzyme prescribing process. Patient’s responses may support the need for a more
behavioural style of approach to the dietetic consultation to ensure better adherence to
therapy and control of symptoms.
2.2 STUDY POPULATION
The study was based on a cross-section of adults with cystic fibrosis, a patient group that the
researcher specifically works with at the Southampton Adult Cystic Fibrosis Centre. At the
time of the study there were 93 full care patients registered with the service. The criteria
stipulated that patients had a confirmed diagnosis of cystic fibrosis, were aged over 16 years
of age and had a FEV1 greater than 30 per cent at the start of the study (See Table 2.1).
Consecutive patients attending the Southampton Adult Cystic Fibrosis Outpatient Clinic were
invited to take part in the study. It was intended to include as many patients as possible.
There were no controls to this study. 
43Table 2.1: Study inclusion and exclusion criteria
Inclusion Criteria Exclusion Criteria
__________________________________________________________________________
Diagnosis of CF confirmed by sweat test Pancreatic sufficiency
or fully informative by genotyping
Aged >16 years  Patients receiving <1500 U lipase/kg/day
                                                                       
FEV1 <30% at the start of the study
__________________________________________________________________________
2.3 ETHICAL CONSIDERATION AND DATA PROTECTION
Informed consent was obtained from all the subjects and the study protocol had the approval
of the Southampton and South West Hampshire Research Ethics Committee (version 2,
Appendix 6). To maintain patient confidentiality, the data extracted from the medical records
and dietetic notes was stored in a computerised database conforming to the Data Protection
Act (Processed June 2004 Appendix 7). As a further precaution, all questionnaires were
coded and a master copy containing the codes and patients names was available only to
Professor Jackson, Director of the Institute of Human Nutrition, University of Southampton
and Jackie Hunt, CF Patient Services Co-ordinator. All records and documents were archived
according to SUHT and University of Southampton guidelines.  
2.4 DATA COLLECTION METHOD
The data was collected cross-sectionally from 08/06/05 to 21/09/05. An outpatient clinic is
held within Southampton General Hospital once a week for the review of adult patients with
Cystic Fibrosis. Figure 2.1 illustrates the selection process for the recruitment of participants.
On arrival at clinic, patients are allocated their own room for infection control purposes.
Individual members of the multidisciplinary team then see the patient (i.e. consultant, nurse,
dietitian, physiotherapist, social worker and pharmacist). The Cystic Fibrosis Trust guidelines
recommend that patients are reviewed on a 3-monthly basis, although some patients will be
seen more frequently. It was therefore expected that over a 3-month period the majority of
patients under the Southampton CF Service will have attended clinic and that this is an ideal
environment in which to recruit participants into the study. Patient appointments for clinic are
kept in the CF office diary enabling planning for the recruitment of new participants.
44Figure 2.1: Selection process for the recruitment of participants
2.4.1 Administration of the questionnaire 
Patient's involvement must be informed and voluntary.  The purpose of the study was
explained to participants in a letter of invitation (Appendix 8) and patient information sheet
(Appendix 9), which was sent out with details of their outpatient appointment at least 1 week
prior to the patient’s clinic date. This gave patients time and space to consider whether or not
they wanted to participate in the study prior to attending clinic.
On arrival at the clinic, it was checked with the patient had received a copy of the Patient
Information Sheet in the post and whether they wished to participate in the study. Patients
were provided with a consent form (Appendix 10) to sign if they decided to become involved.
Lists of patients who had gone through this process were kept so that they were not
approached again at future clinics. Patient names were not added to the questionnaire but
were coded in order to later match with the descriptive data from the medical and dietetic
notes. This ensured that participants remained anonymous and felt safe to reply to questions
in an open and honest way. Patients who consented then completed the questionnaire (See
Appendix 11). 
Patients attending Southampton Adult 
Cystic Fibrosis Outpatient Clinic
Exclude patients with: Pancreatic 
sufficiency
FEV1<30% Lipase Units <1500
Letter of invitation & patient information 
sheet posted prior to clinic appointment
Approached by researcher in clinic 
about willingness to participate
Enrolled Declined
Questionnaires conducted
Exclude incomplete questionnaires
45Patients were left uninterrupted from the clinicians conducting clinic in order for the patients to
be undisrupted. Instructions on the front page requested that the completed questionnaire
was returned into a drop box in the reception area. The investigator remained available for
the duration of the clinic in case there were any questions. After each clinic, the researcher
collected the completed questionnaires (approximately 6-12 per clinic). No further paperwork
or additional questionnaires/ procedures were required from the patient. Throughout the study
period patients continue to receive their habitual CF medication. 
2.5 DESCRIPTIVE DATA COLLECTION
Descriptive data was collected from all the patients who have consented to the study. This
data was be given to Professor Jackson in The Institute of Human Nutrition who can then
match this with the code from the questionnaire. The following descriptive data was collected:
a) Patient characteristics - age, genotype, age at diagnosis, sex, marital status.
b) Clinical measures - Respiratory function (FEV1), Scwachmann score, diabetic status.
c) Relevant medication e.g. PERT and adjunct therapies, enteral feeds, nutritional
supplements.
d) Anthropometry - weight, height, BMI, 
2.6  QUESTIONNAIRE DATA COLLECTION 
2.6.1 Background details of method
The type of method used is dependent on the suitability to the study, population of the study
involved, resources available and suitability for optimal participant involvement. Self-report
measures (face-to-face or telephone interviews, questionnaires, diaries) provide a practical
and flexible method of assessing adherence and a unique opportunity to identify patient
concerns (Svarstad et al1999). Health professionals needing to gather quantitative data from
subjects   frequently   use   questionnaires.   There   are   various   means   of   administering
questionnaires: face-to-face and telephone interviews; mailed and “captive audience” self-
completion questionnaires; computer-assisted techniques (Black et al 1998). The number of
potential participants often dictates the type of study used.  A supervised self-completion
questionnaire was deemed most suitable for this project (See Table 2.2). 
Surveys can be classified as cross-sectional, where a snapshot in time is examined, cohort,
where a group is followed over time or case-control, which generally move back in time from
effect to cause (Daly & Bourke 2000). The project may be classified as being cross-sectional.
46Table 2.2: Advantages and disadvantages of supervised self-completion questionnaire 
(Oppenheim 1990)
Mode of administration  Advantages Disadvantages
________________________________________________________________________
Supervised self- Low cost of data collection              Unsuitable for patients of
completion questionnaire (No postage)              literacy, poor sight etc.
Avoidance of interviewer biasNo opportunity to correct
misunderstandings/further
explanations.
Good response rate No check on completed responses
__________________________________________________________________________
2.6.2 Questionnaire design
The objectives for this phase was to design a questionnaire that specifically addressed the
study hypothesis, aims and objectives. This process essentially followed the steps identified
by Polgar & Thomas (1995) in questionnaire construction:
1. Define the information that is being sought
2. Drafting of the questionnaire
3. Questionnaire pilot
4. Redrafting of the questionnaire
5. Administration of the questionnaire
2.6.3 Definition of the information that is being sought 
There was no existing ‘gold standard’ validated questionnaire available in clinical practice for
identifying how patients utilize their pancreatic enzymes or their attitude towards this type of
therapy. A literature review also did not reveal a suitable tool  from previously published
papers, although they were useful guides (Svarstad et al 1999). In the absence of a gold
standard / validated questionnaire this research questionnaire was designed to answer
questions specific to the projects aims. 
2.6.4 Drafting of the questionnaire 
Table   2.3   demonstrates   the   considerations   required   when   designing   the   survey,   as
suggested by Oppenheim 1996:
47Table 2.3: General considerations when designing a survey
________________________________________________________________________
Considerations Examples
________________________________________________________________________
Type of data collection                                   Interviews, postal questionnaire, observational
techniques.
Method of approach to respondents              Stated purpose of research, confidentiality and
anonymity.
Question sequence                                        Ordering of questions and scales.
Type of questions used                                  Closed questions with pre-coded answer cate-   
 -gories versus free-response questions.          
                                                           
An aim when drafting the questionnaire was that it was easy and non-threatening for the
participants to complete. Personal information such as age and sex was excluded from the
questionnaire as could be collected along with the other descriptive data from the medical
and dietetic notes.  The question sequence used a funnel approach by initially asking simple
multiple choice questions about the participants own enzyme therapy (i.e. type, dose,
frequency). Svarstad et al (1999) in their Brief Medication Questionnaire, addressed patient
concerns or doubts about the efficacy of a given medication as this has been linked to non-
adherence in their previous work. The question “How well does this medication work for you?”
(very well, ok, not well) was therefore adopted in this study. Other indicators of non-
adherence were asked including the frequency that they omit doses of enzymes with meals
and snacks. 
The questionnaire then progresses to the scope of the research with questions about the
participant’s own experience, habits and attitudes. Many of these questions were phrased as
sentences that express a belief, opinion or attitude so that the participant could agree or
disagree with the statement. 
482.6.5 Presentation
Consideration was given to the presentation of the questionnaire, particularly its length and
layout. Appropriate design, in particular a clear, consistent, and uncluttered, can reduce the
perceived  burden  of  response (Black  et  al 1998).  Column  space  to  the right   of  the
questionnaire was dedicated for the coding boxes. This was headed ‘For office use only’ at
the top of the box.
2.6.6 Anticipated response rate
Problems arise  when  a  considerable number  of patients fail to return the  completed
questionnaire or decide not to consent, as this would reduce the sample size, affecting the
statistical power of the study. A high response rate also reduces the risk of bias as
respondents may differ in some way from non-respondents i.e. better motivated, educated
and more likely to adhere to treatment. It is therefore imperative that every effort is made in
gaining the patients co-operation. Initially postal questionnaires were considered, however, a
questionnaire sent out to the home for completion in conjunction with their already time-
consuming treatment regimen is a further interruption. For this reason it was decided that
completion of the questionnaire during clinic time should improve the uptake of participants in
the study. It was anticipated that this study would achieve a good response rate of >75%.
Other attempts to improve response rates included providing anonymity and explaining to
participants on the letter of invitation and patient invitation sheet why this research is relevant
to them. 
2.6.7 Attitude measurement scales
An attitude is the tendency to evaluate something in a particular way (i.e. with some degree of
positivity or negativity). Likert scales are commonly used, which contain a series of opinion
statements assessed for extent of agreement or disagreement on a five-or-seven-point scale.
The responses (e.g. from ‘strongly agree’ to ‘strongly disagree’) are divided into numerically
ordered categories which favourable statements scored five for the ‘strongly agree’ and
unfavourable statements scored one if a total score is being used. 
The questionnaire used mainly closed questions consisting of tick box answers as open
ended questions would be more time consuming and difficult to analyse. However it was felt
important to include some open questions to get participants to explain further and discuss
details of personal experience without prompting them with a selection of answers to choose
from. The language within the questionnaire was informal and familiar to patients and non-
medical terms were used.
492.6.8 Questionnaire pilot and redrafting of the questionnaire
The draft version of the questionnaire was initially tested out on colleagues. It was particularly
helpful getting opinions from other dietitians working in the area of cystic fibrosis to bring their
own experiences and to check the content. It took several draft versions before it was ready
for the pilot stage. With permission from the CF consultant, the questionnaire was piloted on
a small group of patients (n=5) outside the criteria of the main study. This comprised of
inpatients with a FEV1  <30 per cent. This enabled any weaknesses in the design of the
questionnaire to be predicted. A second pilot study would have been ideal following the
necessary alterations but time and patient numbers did not allow this.
2.6.9 Validity & reliability 
Psychometric validation is the process by which an ‘instrument’ is assessed for reliability and
validity through the mounting of a series of defined tests on the population group for whom
the instrument  is intended  (Bowling 2002).  Reliability refers to the reproducibility and
consistency of information. Variation between measurements may have its source in a) the
variation in the characteristic being measured (a lack of ‘constancy’); b) the measuring
instrument, i.e. variation between readings (a lack of precision), or between instruments and
c) the person collecting the information (a lack of ‘objectivity’) (Abramson 1974).  Every
attempt was made to standardise the collection of data, including systematic collection of
data and questions asked in the same way. 
Validity is concerned with accuracy, that is, it measures what it is supposed to measure. i.e. is
the respondent accurately reporting what they do in actual practice. Questionnaires dealing
with personal issues such as adherence and diet will need to be interpreted with caution as
patients may underestimate true practice. Attempts were made to ensure questions weren’t
misleading for participants
Questions on enzyme use could be compared with hospital medical notes and dietetic
records, but these may be out of date or inaccurate. The test of validity is to compare the
respondents account with what actually happened, but this is one of the aims of the study and
difficult to prove. Opinions, beliefs and attitudes are a complex set of behaviours, which are
difficult to measure and validate, therefore you cannot depend upon a single question to
measure vital parts of the study. 
502.6.10 Bias & error 
Bias is a general term for the types of process, which can influence study results leading to
misplaced interpretation (Crombie 1996). There are potential sources of bias particular to
attitudinal studies to be considered in the design and when interpreting the responses. The
types of bias relevant to this study are outlined below.
Selection bias is when patients who take part in studies may differ from those who do not.
Attempts were made to access as many patients as possible in order to get a representative
cross-sectional sample. There was no pre-selection of candidates and all patients were
approached systematically according to when they were due to attend clinic. 
Responding bias  can be due to concepts such as acquiescence (‘yes-saying’), social
desirability and end-aversion bias. Respondents will more frequently endorse a statement
than disagree with its opposite (Bowling 2002).  Alternating the direction of wording of
response choices in Likert scales so that ‘agree’ or ‘disagree’ are not always scored in the
same direction may help to reduce acquiescence but it may instead introduce error when
respondents   fail   to   notice   that   the   direction   has   changed.  Social   desirability   bias
(subconscious wish to present themselves at their best) and faking good effect (deliberate
intention to create a false positive impression) can result in an inaccurate description of ‘true
responses’. To increase the likelihood of obtaining honest answers from the respondent’s
anonymous data collection was used. 
Random measurement error  can occur due to chance from respondents guessing an
answer or giving an inconsistent response. It is usually assumed that most measurement
errors are in different directions and will cancel each other out in an overall scale score
(Bowling 2002). The questionnaire was kept as brief as possible and careful attention was
given to the phrasing of words in an attempt to minimalise error. 
Design bias  –  Attending relevant courses was beneficial  in planning the questionnaire
design. Attention was given to detect and prevent flaws  in the study design, methods,
sampling and analysis to avoid adversely influencing results. 
512.7 STATISTICAL METHODS 
A datasheet in SPSS (Statistical Package for the Social Sciences) version 14.0 was designed
by the researcher. Patient data from the questionnaire and clinical records was then coded
and entered into the database. The data was examined using SPSS to determine if variables
had   been   correctly   defined,   to   check   frequencies   of   variables   and   for   duplicated.
Crosstabulation was used to validate and determine consistency of categorical variables.
Continuous data was checked using histograms. The SPSS database was used to provide
frequencies, descriptive statistics, to crosstabulate data and where relevant to undertake
statistical analysis.
The analyses were conducted using the SPSS version 14 statistical package. Continuous
data were summarised using mean, median, standard deviation (SD), Inter Quartiles Ranges
(IQR) and ranges. Differences were considered to be significant at P < 0.05. Non-parametric
tests were used, when the data was not normally distributed. Pearson correlation and
Spearman’s rank correlation were used to assess the relationship between two continuous
variables.
Categorical data was presented in proportions. Pearson Chi-square test was applied to
assess associations. Where the expected frequency in any crosstabulation fell below five,
Fisher’s exact test was used instead of Pearson Chi square. A p-value of less than 0.05 was
considered statistically significant. Kappa was used to compare the agreement between
dietitian and nurses against that which might be expected by chance.
52CHAPTER 3: RESULTS
Introduction
The data was entered onto SPSS, which initially required two separate databases. The first
contained all the descriptive and demographic data on the cohort, which was collected by the
researcher. The second database collated the responses from the patient questionnaires.
Individuals were anonymously assigned a code number assuring that the information they
provided was confidential. The two databases were merged into one by an independent
source and then analysed. 
This chapter begins with the characteristics of the study cohort, including demographics,
disease severity and nutritional status. This is then followed by the questionnaire responses
which include: the extent of patient adherence to PERT, how well patients understand the
principles of their treatment and the factors associated with inappropriate PERT use. 
3.1 CHARACTERISTICS OF THE COHORT
Patients were recruited from the Southampton Adult Cystic Fibrosis clinic. The application of
questionnaires occurred from 08/06/05 to 21/09/05. At the start of the study there were 93 full
care patients registered with the adult service. From this number, 12 (13%) patients did not
attend their booked outpatient clinic appointment within the recruitment phase. Of the 81
patients who did attend, 30 (32%) patients did not meet the study criteria (pancreatic
sufficient, FEV1 <30%, LU <1000 per day). Of the remaining eligible patients, only 2 (2%)
declined to participate. This resulted in a total of 49 (53%) completed questionnaires and all
were valid (figure 3.1).
3.2 DESCRIPTIVE DATA
The CF team collate patient data in accordance with professional record keeping standards. In
addition, we record information about CF patients for the UK CF database and the South and
West Cystic Fibrosis database to monitor and audit patient care. Variables that are routinely
recorded include date of birth, genotype, marital status, frequency of inpatient and outpatient
visits, medical examination, lung function, investigations, anthropometry and medication. It
was therefore not necessary to repeat these details within the questionnaire, as this was easy
to access and collect separately. This allowed the questionnaire to be used solely for
questions on enzyme practices.
53Figure 3.1: Flowchart of recruitment of participants
Total Number of CF 
Patients 93
Excluded Pancreatic 
Sufficient
FEV1<30%
Lipase Unit <1500
Number excluded = 20
Did not attend clinic
Number excluded = 12
Declined
Number excluded = 2
Review of exclusion criteria
Number excluded  = 10
59 enrolled
49 conducted and 
completed 
questionnaire
73 potential remaining
61 approached at 
clinic
54Forty-nine pancreatic insufficient CF adults participated in the study (22 females; 27 males).
Age ranged from 16 to 54 years, median age 24 years. The age distribution of the cohort is
shown the graph below (figure 3.2) and is representative of the CF population as the majority
of adults are below 30 years of age.
Figure 3.2: Histogram showing age distribution of participants
3.2.1 Marital status
Subjects were similarly distributed between the marital state groups with 40.8% single, 30.6%
with a partner and 28.6% married. Males and females were consistent between marital states.
3.2.2 Age at diagnosis
Age at diagnosis was available for all the participants from The Cystic Fibrosis database records
(Giles & Tyrell 2005). The majority of cases were diagnosed as young babies or children. Table
3.1 shows that a third of participants were diagnosed within the first 3 months after birth.
55Table 3.1: Age at Diagnosis
Age at diagnosis Frequency (%)
0 – 3 months 16 (32.7)
3 -  6 months  6 (12.2)
6 -  9 months 2 (4.1)
9 – 12 months 2 (4.1)
1 - 2  years 7
2 – 3  years 8
4 – 10 years 5
11 – 20 years 3
Total 49 (100)
3.2.3 Genotype
Genotype was available to an extent for all of the participants; 13 of the 49 (27%) subjects
had delta F508 as the first genotype but the second was unknown. This graph shows the
genotype profile of the participants. Over half had the most common CF genotype, delta F508
homozygote (See figure 3.3). 
Figure 3.3: Genotype of participants
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563.2.4 Lung function
Spirometry is the most useful test to monitor routine lung function and is performed at each
clinic visit. Forced expiratory volume in one second (FEV1) can be calculated as a percentage
from the spirometry results, and this provides a useful measure of disease severity. FEV1
predicted measurements of the 49 participants ranged from 31 to 125 per cent (mean 67.2%,
SD 22.0, median 66%). Figure 3.4 is a histogram of the FEV1 values for the cohort and shows
a typical presentation of lung function in adults with CF.
Figure 3.4: Histogram showing the distribution of FEV1 between subjects
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3.2.5 Schwachman score
The Schwachman score is a method of assessing overall disease severity in CF, giving a
result from 0 – 100. A score of >85 is considered excellent, and one of <40 is considered very
severe. It is constructed from four sections: general activity levels; physical examination;
nutritional condition; and chest x-ray. The score was first developed in the 1950s and was
based largely on children; it does not include complications common in adult CF such as
diabetes or osteoporosis (Giles & Tyrell 2005). This score is usually only calculated as part of
the annual review when all the above criteria are assessed. However, if some of the data is
missing then a score cannot be accurately attained. The Schwachman score had not been
performed in 18 of the 49 participants. Scores that were available ranged from 37 to 95
(mean 73.0, SD 13.0, median 74).
573.2.6 Nutritional status
The nutritional status characteristics according to gender can be seen in table 3.2. Body
mass index (BMI) was calculated using the weight and height measures and provides a good
indication of nutritional status. BMI according to the WHO classification must however be
interpreted with caution as the ‘ideal’ weight encompasses a wide range between 18.5 – 25
kg/m
2  and is intended more for the general population rather than those with a chronic
disease. At the Southampton CF centre, a BMI below 20kg/m
2  is considered too low for
optimal lung function and patients would receive nutritional support. A BMI of 22-23 kg/m
2 is
preferable   to   allow   for   times   when   patients   lose   their   appetite   during   an   infective
exacerbation. 
The median BMI was 21.5 kg/m
2 (range 15.4 – 27.2 kg/m
2). Despite the exclusion of patients
with severe lung disease, the data compared well with the South and South West Database
annual report (2005), which showed an average BMI of 21.6 kg/m
2. 
Table 3.2: Nutritional Status of Participants
 
Females Males
Mean (SD) Median Min Max Mean (SD) Median Min Max
WEIGHT 55 (7) 55 39 73 64 (10) 67 38 75
HEIGHT 1.61 (0.06) 1.61 1.51 1.70 1.71 (0.09) 1.73 1.55 1.88
BMI (kg/m2) 21.2 (2.3) 20.9 15.4 25.9 21.6 (2.7) 21.6 16.0 27.2
Ten per cent of the 49-pancreatic insufficient patients had a BMI <18.5 kg/m
2, whereas 84%
had a BMI 18.5 - 25kg/m
2 and 6% had a BMI >25 kg/m
2. As expected, males were taller and
heavier than females. It was observed that of the 49 pancreatic insufficient subjects, 18 (37%)
had Cystic Fibrosis related Diabetes Mellitus (CFDM) and 3 (6%) had an impaired glucose
tolerance (IGT).
BMI was normally distributed (Shapiro-wilks p=0.813) but age was not normally distributed
(Shapiro-wilks p=<0.001). Females showed a weak negative correlation, which was non-
significant (Spearman 0.028, p=0.902). Linear regression showed that age is a significant
predictor for BMI but gender was not. The linear association between BMI and age for males
was a significant correlation (Spearman 0.499, p=0.008). 
58Irrespective of gender, there is a significant unit increase of 0.1 of BMI for every unit increase
in   year   (p=0.013).   Assumptions   associated   with   the   application   of   linear   regression
techniques were assessed and all were satisfied.
Figure 3.5: BMI according to age
3.2.7 Enteral feeding and nutritional supplements
Of the 49 participants, 12 (24.5%) participants were receiving  nutritional support, this
comprised of 3 (6.1%) participants having enteral nutrition via a gastrostomy, and 9 (18.4%)
participants being prescribed oral nutritional supplements. 
3.2.8 Gastrointestinal symptoms and medication
It was beyond the scope of this project to undertake a detailed assessment of patient’s
gastrointestinal (GI) symptoms. Data that was easily available from the dietetic annual review
was collated to get a representation of GI symptoms and relevant medication use. Table 3.3
presents  the   occurrence  of   abdominal   pain  and  prescription  of   adjunct   therapy,   anti-
spasmodic therapy and laxative therapy.  Responses from each participant’s last report
59revealed that the majority reported to have no abdominal pain or bloating (69%). The stool
frequency varied from 1-3 stools per day. GI medication was collected to monitor the extent it
is being used within the CF population. Proton pump inhibitors (PPI) and H2 antagonists act in
the stomach to reduce stomach acid. In CF these medications are considered adjunct therapy
to PERT to prevent the early destruction of the enteric coated capsules. Fifty-five per cent of
participants were prescribed adjunct therapy, all of which were in the form of a PPI.  Laxative
therapy for constipation was indicated in 20% of the cohort, this consisted of lactulose,
movicol and magnesium hydroxide. As with the general population, patients with CF get IBS
symptoms, and for this cohort 10% were on anti-spasmodic therapy (Mebeverine, Alverine,
Colpermin).
Table 3.3: Prevalence of abdominal symptoms, bowel frequency and GI medication use
    Frequency (%)
  Abdominal pain/bloating  
  Yes 15 (31)
  No 34 (69)
  Adjunct therapy  
  Yes 22 (45)
  No 27 (55)
  Anti-spasmodic therapy  
  Yes 5 (10)
  No 44 (90)
  Laxative therapy  
  Yes 11(22)
  No 38 (78)
3.3 QUESTIONNAIRE DATA
The questionnaire aimed to investigate the reality of PERT management. This included the
practicalities of how capsules are taken (swallowed whole or split open; counted out or
roughly estimated; timing), frequency PERT missed with meals and snacks, source of advice
on PERT, adherence and difficulties associated with this therapy.
3.3.1 Enzyme brand use 
With the exception of one patient, all used Creon products. Twenty-nine per cent of
participants   were   on   standard   strength   preparations   of   PERT,   with   the   25,000   UL
preparations being most commonly used (38%), closely followed by the more recently
developed 40,000 UL (33%). Patients vary considerably in the number of capsules of PERT
taken. Data showed that the number of capsules taken per day ranged from 8 to 45 (Mean
17). 
603.3.2 Who gives patients advice on their enzyme therapy?
Participants were asked who they received advice from regarding their PERT. Responses
from the questionnaires showed that advice on PERT were provided by a variety of people;
doctors, dietitians, nurses, GP and family. 
Figure 3.6: Source of advice on PERT
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The most frequent source of advice was from the dietitian. The rationale behind PERT advice
has been outlined in the literature review and we were interested to know whether patients
met these recommendations. The questionnaire was designed with this in mind and the
results are presented as follows.
613.3.3 Recommendation: Capsules should be swallowed whole
Table 3.4: Administration of pancreatic enzyme therapy
Frequency (%)
Swallowing capsules
Swallowed whole 46 (93.9)
Split open 2  (4.1)
Combination of both 1  (2)
Counting out enzymes
Always 33 (67.3)
Usually 10 (20.4)
Never 6  (12.2)
The majority of patients swallow their capsules intact (93.9%), with 3 patients splitting their
capsules open (the contents of which are usually mixed into food which is advocated in
infants and young children because of difficulties swallowing). 
Figure 3.7: Do difficulties swallowing PERT prevent patients from taking their
treatment?
As shown in the figure 3.7, the vast majority had no issues with swallowing their PERT. Two
participants reported to ‘rarely’ have difficulties in these circumstances and these were not
the same patients as previously mentioned who split their capsules open. 
623.3.4 Recommendation: To titrate enzyme dose accordingly
The data for participants practice to count out their PERT are also shown in table 3.4. Whilst
most respondents (67%) said that they always count out the required number of enzymes,
33% “usually” or “never” counted them out. For these patients who approximate the number
of capsules, their estimations could mean that they are taking too many or too few enzymes
with food. We assumed that those patients who were approximating their dose were taking
large doses of capsules but this was not found to be the case. 
3.3.5 Recommendation: PERT should be should be taken before / before and after
meals
There   was   considerable   variation   of   PERT   administration   between   respondents.   As
demonstrated in the figure below, administration of PERT before food tended to be more
frequently preferred (45%), followed by before and during food (29%). 
Figure 3.8: Administration schedule of PERT
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3.3.6 Recommendation: CSM guidelines to not exceed 10,000 UL/kg/d
CSM guidelines recommend that patients do not exceed 10,000 U lipase per kg body weight.
However, as figure 3.9 demonstrates, thirty-seven per cent of participants fall above the
reference line, exceeding the CSM recommendations. 
63Figure 3.9: Units of lipase in relation to BMI
The association between U lipase per kg and BMI was investigated to test whether BMI is a
predictor for U lipase (see figure 3.9). Whilst slight, it was observed that the trend between
BMI and LUKG was negatively correlated and non-significant (-0.130, p=0.388). Linear
regression techniques were applied and borderline significance was found between lower
usage of U lipase and increased BMI (p<0.062).
Patients   on   capsules   containing   40,000   U   lipase   were   more   likely   to   exceed   CSM
recommendations. In view of the fact that higher lipase users tend to be prescribed higher
strength PERT (to reduce capsule numbers), these results were expected.
643.3.7 Recommendation: Enzymes required with all food and drink containing fat
Enzymes are advocated with meals and snacks containing fat. To determine the extent of
non-adherence to PERT, we compared the frequency of missed enzymes with meals and
snacks. Sixty-seven per cent of participants reported to take enzymes with every meal. This
was considerably lower for snacks (35%). Those patients who omit enzymes with meals also
missed enzymes with snacks (r = 30%, p<0.001). There was no correlation between FEV1
and frequency of missed enzymes. A more appropriate use of PERT was observed in
patients with lower as opposed to higher BMI. Gender, marital status and age made no
difference to how enzymes were taken. Table 3.5 shows the extent to which enzymes and
snacks are missed with food. 
Table 3.5: Frequency of missed enzymes
Meals Frequency (%)
Enzymes taken with every meal 33 (67.3)
Miss 1-2 meals per week 13 (26.5)
Miss 3-5 meals per week 2 (4.1)
Miss 6-9 meals per week 1 (2.0)
Do not take enzymes with any meals 0
Snacks
Enzymes taken with every snack 17 (34.7)
Miss 1-2 snacks per week 12 (24.5)
Miss 3-5 snacks per week 11 (22.4)
Miss 6-9 snacks per week 4 (8.2)
Miss > 10 snacks per week 1 (2.0)
Do not take enzymes with any snacks 4 (8.2)
Table 3.6: Crosstabulation between frequency of missed PERT with meals and snacks
Count
Frequency of missed PERT with snacks
Total Taken
Every
Snack
Miss 1-
2
Snacks
Miss 3-
5
Miss 6-
9
Miss
>=10
Do Not
Take
Frequency
of missed
PERT with
meals
Taken Every
Meal 17 8 4 3 0 1 33
Miss 1-2 Meals 0 4 6 0 0 3 13
Miss 3-5 0 0 1 1 0 0 2
Miss 6-9 0 0 0 0 1 0 1
Total 17 12 11 4 1 4 49
Frequency meals/snacks p=<0.001 Fishers Exact.
Predominant majority take and comply with their enzyme therapy.  Of concern are those
patients who miss enzymes frequently with meals and snacks. To determine how accurately
participants adjust their PERT, the questionnaire contained a series of foods and drinks of
varying fat content in which to gauge what enzyme dose they would take (or not as may be
65the case). Enzymes are only required with foods that contain fat; however 20% of participants
took enzymes with food and drink on the list that do not contain fat (fruit and fizzy drinks).
One participant did not know the answer and 1 patient did not complete the answer.
In contrast 29% of participants missed enzymes with at least one of the foods listed that did
contain fat and therefore should necessitate enzymes. Examples of where enzymes were not
taken were with crisps, biscuits and milk. The remaining 71% of the cohort successfully
included the number of PERT that they would take all the foods containing fat.
In the list of foods was ‘cheese sandwich and a packet of crisps’ and ‘packet of crisps’. This
was included with the aim of determining whether patients adjusted their PERT i.e. taking
more enzymes with the sandwich and crisps than just the crisps alone. A total of 78% of
participants did manage this, 10% took a standard dose for both, 10% reported that they did
not eat one of these foods so could not say and one participant (2%) did not answer.
Another gauge of PERT adjustment was to compare whether patients increased their PERT
for the meal and pudding that contained considerably more fat than the other products listed.
The example was a roast dinner with apple pie and custard. The data showed that the
majority (55%) did not adapt their PERT accordingly. Finally the questionnaire included
alcohol as this is an area of debate. Alcohol does not contain fat to ordinarily justify taking
enzymes. However many patients have reported in the passed that they have experienced
abdominal pain or loose stools the day after drinking alcohol without PERT. This could be
solely due to the effects of alcohol on the body or if several units of alcohol are being
consumed then it may justify the need for PERT. Only 3 participants (6%) did take PERT with
alcohol, of which they were patients who never reported abdominal pain at their annual
review so this suggests that they are taking it unnecessarily. Data also showed that a
considerable number of patients do not drink alcohol (18%). 
3.4 What are the patients identifying constraints? 
An aim of the project was to find out what patients identified as constraints to taking PERT
optimally. The questionnaire explained to participants that the questions asked are examples
of circumstances where it may be difficult for some people to take their enzyme therapy and
to choose the answer that comes closest to what they do. The questions and responses are
outlined below.
663.4.1 Eating out
Figure 3.10: Do patients still take their PERT when out?
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The questionnaire asked whether patients still take their enzymes when eating out. Whilst the
majority of participants still managed their enzymes when out, the remaining 36% of
participants reported to miss their enzymes at times (30% “occasionally” and 6% “usually”).
None of the responses included that they never take their enzymes when eating out. The
results suggest that for almost a third of the cohort, being out of the house compromises
PERT use to an extent. Participants were given the opportunity to give personal examples as
to why taking enzymes is problematic when out.
Table 3.7: Responses to why taking PERT is problematic when out of the house
Response Frequency (%)
Forget to carry them 3 (6)
Forget & embarrassing 1 (2)
Don’t have a drink 1 (2)
Total 5 (10)
Although the responses in table 3.7 reflect only a small number of the cohort, they provide a
useful insight for clinicians. One participant gave not having a drink as a reason for not taking
enzymes. This is a practical issue rather than an adherence problem which clinicians can
tend to neglect if it something they had not considered. The remaining examples provided for
why taking PERT is problematic were forgetting and embarrassment. Four of the respondents
gave ‘forgetting’ as their explanation as to why they don’t take PERT when out of the house.
Specific questions regarding this were asked in the questionnaire and are addressed further
in this report.
67No association was found between missing enzymes when out and age, sex, severity of
disease. Patients with a BMI <18.5 kg/m
2 were better at taking their enzymes when out when
compared to the rest of the cohort although no association was found.
3.4.2 Forgetting
Only 9 (18%) participants reported that they ‘never’ forget to take their PERT with the majority
of patients acknowledging that they do have difficulties remembering their PERT. However
crosstabulation of the results showed that participants rarely forget to take their enzymes
when eating out (Fishers Exact, p=0.032).  
Figure 3.11: Forgetting
In this cohort a significant association was found in that patients who were not diabetic were
more adherent than diabetics (Fishers Exact, p=0.048).
A potential difficulty associated with eating out is whether patients are carrying their enzymes
with them. The figure below highlights that carrying enzymes is problematic for some
patients. Only 45% of participants reported to carry their enzymes around with them ‘all the
time’. 
68Figure 3.12: Do participants carry enzymes around with them?
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The questionnaire asked for examples as to why patients don’t carry enzymes around with
them. Five participants responded and all gave examples along a similar theme “forget to fill
pot” and “forget and unaware that would be eating out”.
It was anticipated that it is easier for females to carry enzymes as they can be kept
inconspicuously in a handbag. However men and women showed very similar practices.
There was sufficient evidence to suggest that participants who carry enzymes on them are
more likely to take their enzymes when eating out (Fishers Exact, p=0.011).
Table 3.8: Crosstabulation between carrying enzymes and taking when eating out
Take when eating out?
Total still take usually take
occasionally
take
Carry enzymes
with them
all or time 18 3 1 22
most of time 12 9 1 22
some of time 1 3 1 5
Total 31 15 3 49
Fishers Exact, p=0.011
However,   the   questionnaire   specifically   asked   whether   the   inconvenience   of   carrying
enzymes prevented patients from taking their PERT the findings were contradictory to that
found above.  As figure 3.13 demonstrates only 2 participants were ‘always’ or ‘often’
prevented from taking their PERT due to the inconvenience of carrying their enzymes.
Possible explanations for this lack of consistency could be due to the way the question was
structured or that patients do not want to admit not taking as an actual issue. 
69Figure 3.13: Does the inconvenience of carrying PERT influence whether patients take
them?
703.4.3 Embarrassment
Figure 3.14: Taking enzymes in front of other people is embarrassing
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Just over half of the participants reported to find it embarrassing taking enzymes in front of
other people ‘all of the time’. The varying extent of this is shown in figure 3.14. The
questionnaire asked for examples as to who participants do not take enzymes in front of and
why. Seven out of 49 participants responded with comments that follow a similar theme.
Table 3.9: Examples as to who participants do no take enzymes in front of and why
Responses Frequency (%) 
Only people I know                      1 (2%)
Embarrassing & ask questions 1 (2%)
People who maybe perturbed / curious 1 (2%)
Take discreetly when with strangers 1 (2%)
People I don’t want asking questions 1 (2%)
Strangers as explaining condition get repetitive 1 (2%)
Those I don’t know, don’t want to explain about CF 1 (2%)
Total 7 (14%)
The denominator is 49.
It is well documented in the literature that embarrassment plays an important role in non-
adherence to PERT. Patients were asked whether they ever felt embarrassed taking their
PERT. For 43% of participants, embarrassment was not an issue. However, the remaining
subjects, did to varying degrees, find the process of taking enzymes embarrassing (see figure
3.15). 
71Figure 3.15: Do participants find taking enzymes embarrassing?
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Despite there being an indication from the data that administering enzymes is embarrassing,
this did not appear to prevent participants from taking them when they were out (Fishers
Exact, p=0.066). 
Figure 3.16: Do enzymes prevent patients from eating? 
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The prospect of requiring enzymes with food evidently puts participants off choosing to eat.
Six per cent of participants reported that this occurs ‘a little of the time’ whereas 12% reported
that this occurs ‘some of the time’. A total of 18% therefore have issues regarding the
necessity to take enzymes. However the thought of having to administer enzymes could
affect people in many ways as demonstrated in figure 3.16.
723.4.4 Time constraints 
It was expected that certain situations, such as work and college, may impact on patients
abilities to manage PERT optimally. However as figure 3.17 demonstrates, the majority of
patients did not find work, college, special occasions or poor health to compromise enzyme
use. 
Figure 3.17: Circumstances that prevent patients from taking their PERT optimally
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Possible explanations for such positive responses are that patients who are working or
attending college may be in good health. If this is the case they may be on fewer medications
than those with more severe CF and so there are fewer burdens on managing their PERT.
Also patients in these circumstances may be more motivated to stay well to avoid time off
work, or to avoid the unpleasant side effects of missing PERT when they are around
colleagues. 
Symptoms of CF such as breathlessness, coughing and tiredness may impact on patient’s
ability to take their PERT. However, 84% of participants reported that health problems never
prevented them from taking PERT. Patients, who are having acute problems with their health,
may not want to compromise their symptoms further by omitting their PERT. In addition, if
patients are unwell are likely to be off work or college, therefore have fewer distractions to
interfere with optimal PERT management. 
3.5 Patient attitudes
In order to gain a better perspective of attitudes towards PERT, participants were asked the
extent to which they agree or disagree with the following statements. 
73Table 3.10: Patient attitudes
Patient attitudes Strongly
agree
Agree Undecided Disagree Strongly
disagree
Total
Missing PERT occasionally
doesn’t matter 4 22 4 12 7 49
I don’t take as many capsules as I
am supposed to 0 7 2 29 11 49
I worry about taking too many and
becoming constipated 2 11 4 20 12 49
I intentionally miss PERT to lose
weight 1 0 0 14 34 49
Fifty-four per cent of participants agreed that ‘missing PERT occasionally doesn’t matter’.
These subjects were less adherent at taking PERT with snacks than those who agreed with
the statement (Fishers Exact, p=0.011) (see table 3.10). It was expected that those who
disagreed were more symptomatic to GI disturbances but no association was found when
compared with reported abdominal symptoms and increased bowel frequency. Males were
found to disagree more than females (Fishers Exact, p=0.047).
Table 3.11: Relationships between attitudes, sex and frequency of missed PERT with
snacks
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Taken every
snack 0 4 3 4 6
0.011
Miss 1 - 2
snacks 2 4 1 5 0
Miss 3 - 5
snacks 0 9 0 2 0
Miss 6 - 9
snacks 1 2 0 0 1
Miss >10 snacks 1 0 0 0 0
Do not take 0 3 0 1 0
The question ‘I worry about taking too many enzymes and becoming constipated’ was asked
to determine whether patients were concerned that too many enzymes caused constipation.
The cohort appeared generally unconcerned by this with 65% disagreeing, 8% undecided
and only 27% endorsing this view.
74Missing PERT means that ingested food is not digested properly and the body cannot utilize
the energy from food. Eating disorders are not believed to have a greater incidence in cystic
fibrosis patients but it is perhaps something that is easier to hide and diagnose. With the
exception of one participant, the cohort disagreed with the statement ‘I intentionally miss
taking enzymes to lose weight’. It was a positive finding that so many participants strongly
disagreed with this statement. This patient was an ideal weight. 
Figure 3.18: Is PERT too complicated?
Figure 3.18 indicates that 78% of the sample perceived PERT as uncomplicated to take (i.e.
knowing how many to take, getting the timing right). This was surprising because patients
often report confusion over what they should be doing. It may be that this question wasn’t
clear and that is taken to mean the actual administering of enzymes wasn’t complicated
rather than the process of timing and the titration process.
753.6 How do non-adherent patients differ from adherent patients?
The data was examined more closely to find out the characteristics of patient adherence. This
was done by cross-tabulating the frequency of missed enzymes with meals and snacks and
then devising a scoring system to categorize patients into adherent, partially adherent and
non-adherent groups (see Appendix 12).
Table 3.12: Table showing the prevalence of adherent, partially adherent and non-
adherent CF patients, categorized according to the frequency of missed enzymes with
meals and snacks
Frequency (%)
Adherent 29 (59.2)
Partially adherent 15 (30.6)
Non-adherent 5 (10.2)
Total 49 (100)
There was no association found between the adherence categories when crosstabulated
against age, sex, lung function, gastrointestinal symptoms and medication use and frequency
of inpatient and outpatient visits, see Table 3.13.
76Table 3.13: Association between adherence categories and subject characteristics
ADHERENCE CATEGORIES P-
VALUE
ADHERENT
PARTIALL
Y
ADHERENT
NON-
ADHERENT
SEX Females   13 (26.5%) 8 (16.3%) 1 (2%)
0.44
  Males   16 (32.7%) 7 (14.3%) 4 (8.2%)
MARITAL STATE Married   5 (10.2%) 6 (12.2%) 3 (6.1%) Single >
adherent
than
married 
P=0.07
  Partner   9 (18.4%) 6 (12.2) 0
 
Single   15 (30.6%) 3 (6.1%) 2 (4.1%)
FEV1 FEV1 30-39.9 2 3 0
0.58   FEV1 40-79.9 16 9 3
  FEV1 >80 11 3 2
BMI <18.49   3 1 1
0.11   18.5-
24.9
 
26 12 3
  >25   0 2 1
DIABETIC CFDM   7 (14.3%) 7 (14.3%) 4 (8.2%) CFDM
patients >
non-
adherent
p=0.045*
  IGT   1 (2%) 2 (4.1%) 0
  Normal    21 (42.9%) 6 (12.2%) 1 (2%)
GASTROSTOMY No   28 (57.1%) 13 (26.5%) 5 (10.2%)
0.47
    Yes   1 (2%) 2 (4.1%) 0
SUPPLEMENTS No   22 (44.9%) 14 (28.6%) 4 (8.2%)
0.34
    Yes   7 (14.3%) 1 (2%) 1 (2%)
GI SYMPTOMS Yes   7 (14.3%) 7 (14.3%) 1 (2%)
0.34
  No   22 (44.9%) 8 (16.3%) 4 (8.2%)
77Table 3.14: Association between adherence categories and constraints to enzyme
therapy
 
ADHERENCE CATEGORIES P-
VALUE
ADHERENT
PARTIALLY
ADHERENT
NON-
ADHERENT
Take when eating out
Still take 22 8 1
0.01
Usually take 6 6 3
Occasionally take 1 1 1
Never take 0 0 0
Carry enzymes around
All of the time 16 4 2
0.05
Most of the time 12 8 2
Some of the time 1 3 1
Never 0 0 0
Take enzymes in company
All of the time 15 9 3
0.80
Most of the time 8 2 1
Some of the time 3 3 0
A little of the time 3 1 1
Prevents them from eating
Some of the time 5 1 0
0.5 A little of the time 3 0 0
Never 21 14 5
Embarrassment
Always 0 0 1
0.80
A good bit 3 0 0
Some of the time 4 2 1
A little of the time 9 6 2
Never 13 7 1
3.7 What compromises ‘best practice’ and how can this be identified in clinical
practice?
From the results, five aspects were identified as compromising best practice for PERT usage.
These were: 1) missing PERT with one meal or more per week, 2) missing PERT with more
than 2 snacks per week, 3) splitting PERT capsules open, instead of swallowing intact, 4) not
carrying PERT around and 5) not adjusting PERT according to the fat content of food. These
were chosen because they were either the strongest indicators distinguishing non-adherence
or were practices considered to have the most detrimental effect on the digestion of nutrients.
Table 3.15 shows the prevalence of these occurrences within the cohort. 
Table 3.15: Prevalence of PERT usage that compromises ‘best practice’
Prevalence
78No Yes
Miss with meals >once
per week 33 (67.3%) 16 (32.7%)
Miss with snacks twice
or more per week 29 (59.2%) 20 (40.8%)
Split enzyme capsules
open 46 (93.9%) 3 (6.1%)
Do not carry around  22 (44.9%) 27 (55.1%)
Do not titrate according
to the fat content of food 26 (52%) 23 (46.9%)
The assessment tool in Figure 3.19 was devised to differentiate between patients who have
the most prudent PERT use and those that are compromising their therapy. A scoring system
was developed to identify risk, taking nutritional status and GI symptoms into consideration. 
Figure 3.19: Assessment tool
Using the assessment tool it was possible to categorize patient’s PERT use into low risk
(42.8%), medium risk (26.5%) and high risk (30.6%) as demonstrated in Table 3.16. The
same could be done for nutritional status (see Table 3.17). It was then possible to categorize
those participants who were not taking pert optimally according to their nutritional status
score (Table 3.18). This showed that patients with medium to high risk nutritional status score
were having difficulties taking their PERT optimally. From these two groups, not carrying their
PERT around and not titrating according to the fat content of food were the most frequently
reported problems. Crosstabulating the PERT usage score and the nutritional status score
STEP 1: PERT USAGE
1 point for each question answered yes
Miss PERT with >1 meal / week? 
Miss PERT with >2 snacks / week? 
Enzyme capsule split open? 
Do not carry enzyme around? 
Do not adjust PERT according to fat? 
STEP 2: PERT USAGE SCORE
Add scores from STEP 1.
  0-1 = Low risk
     2 = Medium risk
   3+ = High risk
STEP 3: BMI 
SCORE
BMI > 20 = 0
BMI 18.5 – 19.9 = 1
BMI <18.5 = 2
STEP 4: GI SCORE
No abdominal pain/loose stools/DIOS = 0
Intermittent abdominal pain/loose stools/DIOS = 1
Frequent abdominal pain/steatorrhoea/DIOS = 2
STEP 5: NUTRITIONAL STATUS SCORE
Add scores from STEPS 3 & 4.
   0 = Low risk
1-2 = Medium risk
 3+ = High risk
79(Table 3.19) reassuringly found a low incidence of participants with high risk scores for both
PERT usage and nutritional status (n=1). 
Table 3.16: Categories of risk according to PERT usage score
PERT USAGE SCORE
LOW RISK
(0-1)
MEDIUM
RISK (2)
HIGH RISK
(3+)
21 (42.8%) 13 (26.5%) 15 (30.6%)
Table 3.17: Categories of risk according to Nutritional Status score
NUTRITIONAL STATUS SCORE
LOW RISK
(0)
MEDIUM RISK
(1-2)
HIGH RISK
(3+)
24 (49%) 22 (44.9%) 3 (6.1%)
Table 3.18: Poor PERT usage and Nutritional Status risk
NUTRITIONAL STATUS SCORE
LOW RISK MEDIUM RISK HIGH RISK
Miss with meals >once per week (16)  9 5 2
Miss with snacks twice or more per week (20) 10 7 3
Split enzyme capsules open (3) 1 1 1
Do not carry around  (27) 13 9 5
Do not titrate according to the fat content of food (23) 11 8 4
Table 3.19: Crosstabulation of PERT usage score and Nutritional Status score 
NUTRITIONAL STATUS SCORE
Total
0 1 2 3
PERT
USAGE
SCORE
0 3 4 1 0 8
1 7 4 2 0 13
2 6 4 1 2 13
3+ 8 5 1 1 15
Total 24 17 5 3 49
3.8 Is PERT use related to disease outcome?
This study excluded patients with the most severe lung function (FEV1  <30%). However
patients with an FEV1 between 30 – 40% are still classified with severe lung function. Of this
group of patients none were classified as non-adherent according to the degree of missed
enzymes with meals and snacks, although no statistical association was found.
80Non-adherence was found to be less prevalent in underweight patients. Therefore patients
with better nutritional status based on their BMI were more likely to miss taking their PERT.
No association was found between non-adherence and increased frequency of bowel
frequency, reported abdominal pain and use of medication for gastrointestinal purposes.
3.9 Predicting adherence
Monitoring patients with CF over time can lead health professionals to make assumptions as
to how adherent they are. This in turn may influence the advice clinicians give to patients. We
were therefore interested to know whether these ‘instincts’ are a help or hindrance in the
consultation process. Nurse specialists probably know patients better than other members of
the multidisciplinary team. We gave two adult CF nurses a list of the recruited participant’s
and asked them to rank them as either adherent or non-adherent. The dietitian was also
asked, although she could only comment on the nutritional aspects of the treatment regime.
We were interested to know whether nurses and dietitian shared assumptions and whether
these predictions correlated with the results on patient adherence levels to PERT.
Of the 49 participants, the specialist nurses classified 63% participants (n=31) as adherent,
whereas the dietitian classified 75.5% (n=37). The two specialties agreed that the participants
were adherent in 55% of cases (n=27) and non-adherent in 8 cases (16.3%). In 8% of the
participants who the nurses believed to be adherent, the dietitian did not agree. Twenty per
cent of the participants that they dietitian classified as adherent, the nurses predicted non-
adherent.
Table 3.20: Nurses and dietitians predictions of patient adherence and non-adherence
_________NURSES
_
DIETITIAN _______
NON-ADHERENT ADHERENT
NON-ADHERENT 8 (16.3%) 4 (8.2%)
ADHERENT 10 (20.4%) 27 (55.1%)
Fishers Exact p=0.019
Kappa 0.013
A relationship was found between the participants who the dietitian classified as adherent and
an ideal BMI (Fishers Exact, p=0.022). No association was found between nurse predicted
adherence and BMI.
Table 3.21: Dietitians predictions of patient adherence
 
Dietitian
predictions as
Adherent
Dietitian
predictions as
Non-adherent
P-Value
81BMI WHO Categories
Underweight  (BMI<18.5) 1 4
0.022 Ideal weight (BMI 18.5-25) 33 8
Overweight (BMI>25) 3 0
Prescribed supplements
Yes 4 5
0.029 No 33 7
Frequency of missed PERT
Adherent category 23 6
0.624 Partially adherent category 11 4
Non-adherent category 3 2
No correlation was found between clinicians (dietitian and nurses) predictions of patient
adherence and adherence to PERT (frequency of missed enzymes), suggesting clinicians are
poor indicators assessing individual adherence.
3.10 Case studies
Data on the participants who frequently missed enzymes were examined in more detail and it
provided a representation of patients enzyme practices that are best described as case
studies. Three examples are detailed below with suggestions of where things are going
wrong and what improvements could be made.
Case study 1
18-year old female
Lung function: FEV1 78%. No inpatient admissions and 5 outpatient appointments in the
past 12 months.
Nutritional status: BMI 22 kg/m², CFDM
PERT:  Creon 25,000 - 10 capsules per day (4310 LU/kg/d). Theses are counted out,
swallowed whole and taken before, during and after food. Misses PERT with 6-9 meals per
week and >10 snacks per week. She reports symptoms of abdominal pain. Bowels are open
twice a day. Enzyme therapy works ‘ok’ for her. She is prescribed a proton pump inhibitor and
takes lactulose. She receives ‘occasional’ advice from the doctors, dietitian and family
regarding her enzyme therapy. 
It is ‘always’ embarrassing taking enzymes. She takes enzymes in front of people ‘most of the
time’ but gave the example response ‘it’s embarrassing and people ask questions’. She also
reports that she ‘often’ forgets them. She ‘usually’ takes enzymes when eating out and carries
enzymes around ‘most of the time’. She has no problems finding the time to take enzymes at
college, at home and when unwell but for special occasions she does often miss.
82Comment: This case study describes a young lady with good nutritional status and lung
function. However she does not take PERT with a considerable number of meals and snacks.
In view of her good lung function and nutritional status it could be presumed that she is
generally managing well and dietetic input may be minimal. However she reports abdominal
symptoms which have probably resulted in the prescription of a proton pump inhibitor and
lactulose.   Determining   the  reasons  for  non-adherence  to enzymes  and  improving   the
situation may have led to an improvement in gastrointestinal symptoms. Instead, it has
resulted in her being prescribed two potentially unnecessary medications. It can be estimated
that one meal and 1-2 snacks per day are taken without PERT and the reasons behind this
appear to be forgetting to take and embarrassment. It is simply not enough to recommend
routine use of PERT, clinicians need to be able to identify circumstances that make taking
PERT difficult and practical strategies to help.
Case study 2
19-year-old single male
Lung function: FEV1 55%, 1 inpatient stay and 10 outpatient visits in the past 12 months.
Nutritional status: BMI 16.5 kg/m². CFRD. No feeds or supplements.
PERT:  Creon 25,000 - 30 capsules per day (14,124 LU/kg/d). These are counted out,
swallowed whole and taken before and during meals. PERT is taken with every meal but
missed with 6-9 snacks per week. He reports symptoms of abdominal pain. Bowels are open
twice a day. No adjunct therapy is prescribed. Enzyme therapy works “very well”. He receives
‘frequent’ advice from the dietitian and his family regarding his enzyme therapy.
It is ‘never’ embarrassing for him to take enzymes and he still manages to take them when
eating out. He takes PERT in front of people ‘all of the time’. He reports that he ‘sometimes’
forgets to take them“. Enzymes are carried on him ‘most of the time’. There is ‘sometimes’ no
time to take PERT at college and when there is a special occasion, but never misses them at
home or when he has problems with his health. 
Comment: This case describes a young man with moderate lung function. We have come to
expect good lung function from patients on transition to the adult service, and his poor
nutritional status may be partly to blame for this. He is not taking any nutritional supplements
or enteral feeds. With such a low weight it is very likely that this will have been previously
recommended, which suggests that the patient has declined to take them. He is managing to
take his enzymes well with meals but misses frequently with snacks. If the energy from
snacks were fully utilized with optimal PERT, then weight gain is likely to be achieved. From
his responses in the questionnaire, he does not appear to present any specific issue as to
83why he doesn’t manage enzymes with all of his snacks, other than he sometimes forgets.
Issues’ regarding his poor weight and inadequate PERT use need to be tackled in a fresh
way as previous advice has obviously had no benefit. 
Case study 3
18-year-old single male.
Lung function: FEV1 120%, No inpatient stays and 5 outpatient visits in the past 12 months.
Nutritional status: BMI 17.4 kg/m². CFDM. No feeds or supplements
PERT: Creon 10,000 - 8 capsules per day (538 LU/kg/d). No adjunct therapy. These are
counted out, swallowed whole and taken during food. PERT is taken with every meal but no
snacks. He reports no abdominal pain. Bowels are open 2-3 times per day. No adjunct
therapy is prescribed. Enzyme therapy works “very well”. He receives occasional advice from
the doctor on his enzyme therapy. 
Taking enzymes is embarrassing ‘some of the time’. He still manages to take them when
eating out. He has no problems taking PERT in front of other people. He finds the time to take
PERT at college, home, special occasions and when health is a problem.
Comment: This young man has exceptional lung function despite his low BMI. This is a
classic example of where if this patient had presented in clinic we would have gone down the
route of discussing the need for nutritional supplements. However, as a first line it is probably
more appropriate and cost effective to ensure optimal digestion of the food he is currently
managing and this may be enough to achieve his target weight. He is on a relatively low dose
of PERT. However this is only being taken with meals and not snacks. This is a common
assumption that PERT is only required with meals yet snacks can often be high in fat. He
reports no abdominal pain which may indicate that he is asymptomatic if maldigestion occurs.
A trial of PERT with all snacks containing fat is recommended to determine whether an
improvement can be seen. Not taking PERT with snacks could have arisen due to the
embarrassment of having to take in front of other people therefore requires investigation. 
To conclude, the case presentations were chosen due to frequently missing PERT with food.
Coincidently, all three cases had recently been transferred from paediatrics and were
therefore relatively new to the service. It is unclear whether their inappropriate PERT use
would have been identified as patients became established with the service or whether these
were issues that we would never have been detected.  Two out of the three individuals had
CFDM and the data did identify that diabetic patients were more likely to be non-adherent
than non-diabetics.
8485CHAPTER 4: DISCUSSION AND CONCLUSION 
4.1 INTRODUCTION
Individuals differ in their requirements for PERT and their ability to adhere to advice optimally.
PERT plays a fundamental role in the nutritional management of patients with CF and under
the   supervision   of   the   dietitian,   patients   self-titrate   their   enzyme   therapy.   Pancreatic
insufficient patients are on PERT for life, together with the financial and health costs,
considerable time and effort is invested in this task. There are however limited resources to
monitor the effectiveness of treatment, with the only accurate way is to collect stool samples.
A 3-day faecal fat balance study is considered the gold standard for assessing fat absorption.
This test was withdrawn from the SUHT laboratory mainly because stool collection is difficult
and unpleasant for patients. The process of adjusting PERT therefore remains a system of
trial and error, with the CF dietitian reliant on patient self-reporting. There are several
problems with this; 
• Patients may say they have no problems to avoid sensitive and embarrassing
discussions about their bowel habits.
• Individuals may become accustomed to symptoms of maldigestion and malabsorption
to the extent that for them it becomes ‘normal’ to them.
• Patients rarely disclose problems of non-adherence and the dietitian rarely asks due
to the time constraints of the clinic environment and uncertainty in dealing with this
type of ‘difficult information’.
• Patients may not acknowledge that they have adherence problems when they are
face-to-face with the dietitian because they do not want to disappoint them or because
they are in denial of the problem. 
In the absence of accurate information on what the patient is doing, the dietitian can never be
certain that the information offered has been understood by the patient or even if it was the
most appropriate recommendation for their situation. The study attempted to look at factors
that   may   precipitate   and   reinforce   adherent   behaviours   in   CF   patients   on   PERT.   A
questionnaire was designed with the specific aims to understand patient’s knowledge, the
practical difficulties experienced by patients towards their enzyme management and if dietetic
advice is effective. This chapter summarises the project findings, drawing comparisons with
results   from   published   studies,   discussing   the   project   limitations   and   making
recommendations for practice based on the findings of the research.
864.2 DISCUSSION OF MAIN FINDINGS
4.2.1 Are patients doing what they should? 
This study measured patient practices within our clinic population against those that are
considered best practice. There are also areas of PERT that remain controversial and as a
consequence practice differs between regional services (i.e. to not exceed 10,000 UL/kg/d,
and ideal timing to take PERT). It was therefore felt important to measure these aspects for
comparison. 
The expert committee of the ‘Nutritional Management of Cystic Fibrosis’ (CF Trust 2002)
recommends that children should be encouraged to swallow whole enzyme capsules at the
earliest opportunity. Children should be encouraged to swallow whole enzyme capsules at
the earliest opportunity (CF Trust 2002). Occasionally patients reach the adult service and
continue to split their enzyme capsules open. Questions regarding this were included in the
questionnaire to monitor the current situation in the clinic population. A total of three patients
were found to split their enzymes open, where previously we were only aware of one patient
who did this. Although no association was found, it is interesting to note that of the three
patients, two reported abdominal pain at their annual review. Enzyme capsules are enteric
coated to protect the microspheres within from being released too early and thus susceptible
to acid degradation. Enzyme capsules that are split open are therefore less effective,
compromising the digestion of nutrients. Patients who have difficulties swallowing PERT
capsules whole are also likely to have problems swallowing other medication. These issues
confirm that we are not always aware of what our patients are doing and a need to identify
these patients early so that they can get help overcoming this. 
A third of participants were found to estimate their dose rather than counting out the exact
quantity. This is likely to occur to save patients time, although another possibility is that PERT
may be perceived more as a food supplement than a medication resulting in a more blasé
approach to treatment. It was hypothesized that patients requiring large doses with meals and
snacks would be more likely to fall into this category but this was not found to be the case.
This issue is of concern because patients may be under or over prescribing unnecessarily.
However, it is also worth considering that patients with a relaxed attitude to their enzyme use
may be a positive thing, in that they cope better with this aspect of their treatment.
87A wide variation in PERT administration schedules was seen amongst the cohort, which
perhaps reflects the general lack of consensus found in the literature as to what is the optimal
timing. The practice at Southampton is to recommend taking before, or before and during
food and this was what the majority of patients were doing. Patients who take PERT at all
other times does not necessarily imply non-adherence. Over time patients are likely to have
received advice from different dietitians and other clinicians, which is particularly the case if
they have moved between different regional services. Individual transit time has been found
to be variable (Taylor et al 1999), therefore patients who report symptoms of maldigestion are
advised to trial taking their PERT at different stages of the meal in an attempt to improve
effectiveness. Even with more trials, it may remain an area where due to the individual
variation in the way patients handle digestion it is impossible to be so prescriptive about the
timing of enzyme ingestion. 
CSM recommendations state that ‘it would be prudent for patients with CF not to exceed
10,000 IU lipase/kg/day regardless of which preparation is used’. Thirty-seven per cent of the
study cohort took in excess of 10,000 U lipase/kg/d. Increased U lipase/kg/d was not found to
be associated with increased abdominal symptoms, stool frequency or GI medication use.
Studies by Beckles Wilson et al (1998) and Lowdon et al (1998) showed that doses of U
lipase can be reduced and nutritional status maintained in children with tight supervision and
dietetic intervention. These studies have not been attempted in adult patients and with limited
evidence it remains unclear whether excess lipase is detrimental in clinical practice. The data
from this study found a slight trend between BMI and LUKG. The vast majority of patients
who exceeded 10,000 LU/Kg/d had a BMI between 18.5 – 25 kg/m
2. For patients who are
doing well it raises the question as to whether we should change their practice and even if we
did would patients be willing to make changes if what they are doing works for them? Further
investigations are required to determine whether increased U lipase is associated with
patients having a better nutritional status or whether patients with a good nutritional status
have less supervision resulting in over using PERT. The UK CF Database (2006) made no
reference to U lipase/kg/d in the CF population despite this being collected by clinics. CF
centres need to share information on their populations enzyme use if we are to get a realistic
impression of what patients are doing and occurences of FC. 
PERT is recommended with all foods and drink containing fat. However, only 67% of
respondents managed this routinely with all meals, and for snacks it was considerably lower
at 35% (see Table 3.4). A relationship was seen in that patients who omit PERT with meals
88also missed with snacks (see Table 3.5). Other studies have shown patients adhere better
with meals than snacks, although exact comparison is difficult due to the different ways that
adherence has been measured and defined. Conway et al (1996) studied 80 adolescents and
adults and found that 85% of the subjects reported good, and 12% reported moderate PERT
adherence with meals; whereas 38% reported good, 36% moderate and 20% reported poor
adherence with snacks. Schall et al (2006) in their study of preadolescent children found that
84% to 96% of the subjects having 80% or better adherence to PERT for meals but only 50%
to 70% for snacks. It was hypothesized that there would be an association between
underweight patients and increased frequency of missed enzymes. However the opposite
was found to be the case, a more appropriate use of PERT was seen in patients with lower
as opposed to higher BMI. Schall et al (2006) also found this to be the case in children. The
dietitian reviews underweight patients more frequently, it is therefore a positive finding that
intervention appears successful. 
Patients are advised to titrate their PERT according to the fat content of food and drink.
Currently enzyme use is monitored through the use of food diaries. These are sent out to
each patient prior to his or her annual review appointment. Completed food diaries are
extremely useful for monitoring daily PERT dose, eating patterns, whether the diet is
adequately fortified and if patients are adjusting PERT according to the fat content of food.
Entering the 5-day food diary into a computer programme can perform further analysis. This
provides   average   daily   nutrient   values   to   determine   whether   patient’s   current   diet   is
adequate. If energy intake is in excess of the individual requirements it can help identify
maldigestion. Analysis can also be used to determine the fat contents of meals and snacks,
which can then be compared with PERT dose.  The disadvantages of food diaries are that
they are time consuming to analyse and for patients to complete. As a result some patients
routinely do not return them so it can never be attained how well they are managing. Food
diaries are also subject to error, as patients may underestimate or overestimate quantities
consumed. Also, these diaries have been known to be completed by the parents or partner of
the patient so there were doubts as to how much dietitians can rely on the accuracy of them. 
The questionnaire contained a list of food and drink of varying fat content and participants
were asked to add how many enzyme capsules they would usually take. The data showed
that 29% of patients missed PERT with at least one of the foods or drinks from the list that
contained fat. Examples where enzymes were missed were crisps, biscuits and a glass of full
fat milk. Traditionally, enzymes have been prescribed on the basis of one dose for meals and
89a smaller dose for snacks and this was reflected in the results, albeit in a small proportion of
the patients (10%). Better control of enzyme dose can be achieved by titrating dose against
the fat content of food (Beckles Willson et al 1998). It was therefore positive to see that this
was occurring in the vast majority of patients (78%).
The data also found that 20% of patients took PERT with food and drink that did not contain
any fat. The responses showed that patients took enzymes with fruit and fizzy drinks
indicating that knowledge or misconceptions surrounding their treatment are the problem
rather than adherence. Those patients who do not take their PERT routinely may be doing so
because they are asymptomatic or if they do get adverse GI symptoms it may not be enough
to justify the impracticality that taking enzymes causes them. Alternatively patients may
accept that symptoms are part of their CF or not even relate it to inadequate enzymes. This
supports the need for further education. McCabe (1996) looked at knowledge of nutrition and
pancreatic enzymes in 21 children. The study showed that the patients were unaware of
common foods contained fat and that enzymes were taken unnecessarily with foods low in
fat. There was a lack of understanding regarding the titration of enzymes to different foods. 
4.2.2 What constraints do patients identify? 
Non-adherence was not associated to an individual cause but associated with a variety of
factors. The results demonstrated that as well as the practical issues, there is a psychosocial
impact associated with PERT. Ideally patients need to carry enzymes on them at all times to
allow for the spontaneity of eating whenever  and whenever  the situation arises.  The
practicality   of   how   successfully   this   is   managed   in   adults   has   not   previously   been
investigated. Pancreatic enzymes typically come in pots of 100 capsules, which are too bulky
to carry around all of the time. For this reason patients are known to keep spare pots in the
car, at work and the homes of friends and family. Compact enzyme containers are available
for patients to store their daily use; alternatively some patients prefer to keep the capsules
loose in their pockets. Eating out is often for convenience or special occasions, in which case
portions consumed are potentially larger and more energy dense than usual intake. The
consequence of missing enzymes at these times is that the energy and nutrients consumed
are not digested effectively. This ‘wasted opportunity’ could amount to a considerable amount
of calories over time. Figure 4.1 illustrates how individual patients can respond to eating
outside of the home and the possible outcomes. 
90The data showed that whilst 45% of participants carried PERT with them ‘all of the time’, a
further 45% managed to ‘most of the time’ and 10% did ‘some of the time’. Analysis revealed
that patients who carried their PERT were more likely to take them when out (p=0.01). Figure
4.1 demonstrates that if patients are not carrying their PERT with them then it can impact on
their decision to eat. Patients then either have to make the decision to go without food or eat
without PERT. Either way the outcome is not optimal, resulting in reduced dietary intake or
impaired digestion of nutrients. Previous studies have found that ‘forgetting’ to take PERT
was a common factor in patients explanations for not taking their PERT (Abbott et al 1994,
Conway et al 1996), however this study showed that patients rarely forget to take their
enzymes when eating out (Fishers Exact, p=0.032).  
Figure 4.1: Conceptual framework illustrating the possible factors constraining
adherence to PERT
The diagram also demonstrates that just because patients carry PERT on them it does not
necessarily mean they will take them with food. Embarrassment was identified as a reason
for not carrying and taking PERT. Participants showed concerns in taking medication in front
of people that they do not know well. Seven patients provided very insightful examples as to
why it is difficult to take PERT in front of other people. The general consensus was that they
are aware it draws attention to themselves; people are curious and ask questions and they
Out of the house
Go without food. Eat without PERT. Eat & take PERT.
Carrying PERT?
Still eat?
Feel embarrassed?
Eat?
Yes No
Yes
No
Yes
No
Yes
91feel obliged to explain their condition. There will be occasions when it is difficult for patients to
take their enzymes discreetly and understandably not taking them means that at that point in
time they are not reminded of their disease and its implications.
The questionnaire measured the frequency of missed PERT with meals and snacks. From
this data it was possible to differentiate the characteristics of adherent, partially adherent and
non-adherent patients. Based on the criteria that defined adherence (see Appendix 12), 59%
of participants were classified as adherent, which is a positive finding. For the remainder of
the cohort, 31% were partially adherent and 10% were non-adherent. In view of the fact that
this study was anonymous, it raises the dilemma as to how we identify these patients in the
future? During the dietetic annual review patients are currently asked how frequently they
miss taking their PERT but the responses are typically ‘never’ or ‘rarely’ which provides little
insight into the extent of the problem. Patients completing the questionnaire perhaps gave a
more realistic and honest response because the frequency scale may have made it more
acceptable to acknowledge. Determinants of PERT non-adherence were hypothesised to be
linked with feelings of embarrassment and issues taking enzymes in front of other people,
however no association was found.  Age, sex, lung function, gastrointestinal symptoms,
inpatient and outpatient visits were also found to make no difference to adherence. Patients
with CFDM were found to be more non-adherent that their non-diabetic counterparts. This
suggests that the burden of coping with what is another disease in its own right may at times
be too much to deal with. 
4.2.4 Does a lack of knowledge account for patients not doing what they should?
Many barriers were attributable to patient’s lack of knowledge on PERT adjustment, showing
that poor adherence can be unintentional. Knowing what foods require enzymes and what
foods did not was identified as an area of limited understanding. Patients had a poor
knowledge of titrating their PERT according to the fat content of food and drinks. The survey
also identified that patients frequently miss PERT with snacks, which again may be because
they are unaware of the fat content of foods they are eating and the necessity for PERT.  
Prior to this study we overestimated patient’s knowledge of PERT by presuming that patients
were well informed on transfer to the adult service. There is a sense that patients have heard
it all before and we don’t want to be repeating information. As a result of this, education tends
to occur only when problems arise. This sporadic approach to advice is seen throughout the
MDT and there is no formal education programme for CF patients. When patients attend
clinic they are seen by multiple health professionals over a relatively short period of time. This
92is when they deal with any current issues, receive advice and treatments and medications will
be   adapted.   This   environment   must   be   overwhelming   for   many   patients   and   it   is
unreasonable to expect them to retain everything. 
Giving out all the information in one consultation is likely to be too much for the patient to take
in. Patients may welcome confirmation and encouragement about what they are doing well.
Education therefore needs to be more comprehensive and tailored according to the problems
identified by the patient. An individual session as opposed to group education is necessary
because of microbial contamination. 
As demonstrated in the literature review, education alone is not enough to bring about
change. What patients know and what they do in practice are not necessarily the same.
Several studies have already demonstrated this successfully for improving calorie intake and
treatment in CF (Stapleton et al 1999, Jelalian et al 1998). However, Haynes et al (2005) in a
Cochrane  review   of  interventions   to  enhance  medication   adherence  found  that   whilst
improving   short-term   adherence  is   relatively  successful,   current   methods  of   improving
adherence for chronic health problems are mostly complex and not very effective, so that the
full benefits of treatment cannot be realized. Rather than dismissing the idea of behavioural
interventions   on   the   grounds  of   limited   evidence,   more   innovative   ideas   need   to  be
investigated.
4.2.5 Are clinicians able to predict adherence?
Dietitians and nurses had a reasonably good level of agreement when classifying patients as
adherent   or   non-adherent.   However,   it   appears   that   the   dietitian   inadvertently   based
adherence with good nutritional status, yet the data revealed the opposite to be the case.
When comparing the data on the frequency of missed enzymes, the dietitian and nurses were
found to be poor predictors of patient adherence. Roth & Caron (1978) found that physicians’
judgments were significantly better than chance but nethertheless low in accuracy, which did
not   improve   as   they   gained   familiarity   with   the   patient.  There   are   several   possible
explanations as to why discrepancies exist including clinicians paying more attention to
objective clinical findings than to patient subjective reports; lacking the expertise or time to
assess adherence; and patients may be reluctant to disclose non-adherence because of
concerns about social desirability, reluctance to disappoint the physician, or fears of having
medications withheld (Murri et al 2002). The questionnaire was anonymous, therefore there is
no way to distinguish which patients had poor PERT practices. Rather than clinicians relying
on their judgment, better tools are needed to identify issues of adherence. The questionnaire
93has been a useful research instrument, and aspects within this could be adapted as a
screening method to gain a subjective perspective of patient’s enzyme management and
identify patients who need support. 
4.2.6 Triage and Assessment tool
The results showed a less optimal enzyme use in patients with an ideal weight. It is unclear
whether   this   is   because   this   group   of   patients   have   received   less   intervention   than
underweight patients and as a result their knowledge is poor. Another likelihood is that they
are asymptomatic to steatorrhoea and abdominal pain. No association was found between
the frequency of abdominal symptoms and weight, therefore it cannot be assumed that
patients with a good BMI are less symptomatic, however it is understandable that they may
have less incentive to adhere if they are an ideal weight. It is well accepted that patient
perception of ‘normal’ stools can differ from what is ideal. 
The aim is to do the best for the most number of patients and when faced with an ever
expanding adult CF service this means prioritising dietetic management to the needs of the
individual. Patients who are managing their therapy well will not want to be bothered with
unnecessary  input.  This  raises the dilemma as to how  we  identify  patients who  are
maldigesting but have an ideal weight.  As a result of enhanced awareness, care can be
strategically   designed   to   improve   our   service.   Information   can   now   be   targeted   and
communication   improved   if   adults   existing   knowledge   is   established.   It   has   identified
educational needs regarding the administration of PERT; particularly that patients need more
education on the varying fat content of food. 
Triage is a system used by medical personnel to sort patients into three categories so as to
allocate resources most effectively. An analysis of patient’s PERT usage and their nutritional
status could help determine whether they are low, medium or high risk of intervention (See
Figure 4.2). 
Figure 4.2: Triage
Triage
PERT usage
Nutritional status
Low risk
Medium risk
High risk
94Based upon this principle, a screening tool was developed (see Figure 4.3). Five key areas
from the results were identified as compromising best practice for PERT use which were: 1)
missing PERT with one meal or more per week, 2) missing PERT with more than 2 snacks
per week, 3) splitting PERT capsules open, instead of swallowing intact, 4) not carrying PERT
around and 5) not adjusting PERT according to the fat content of food (see step 1 in Figure
4.3). 
Figure 4.3: Assessment tool
These assessments include both knowledge and adherence measures. Scoring patients
depending on the criteria in step 1 can differentiate between patients who have the most
prudent PERT use and those that are compromising their therapy (step 2). However, this
alone is not enough to assess risk, as the consequence of this is dependent on nutritional
status. Patients who are not taking their PERT optimally are more at risk if they are very
underweight (step 3). The tool also screens for patients who may have an optimal weight but
are experiencing gastrointestinal symptoms (step 4). BMI and symptoms can be calculated to
provide a nutritional status risk score (step 5). This assessment tool provides a common
sense approach to treatment intervention. For example;
• Patients with a good nutritional status scores and good PERT usage score requires
little intervention.
• Patients with low risk PERT usage score but high risk nutritional status score requires
solely nutritional support intervention.
STEP 1: PERT USAGE
1 point for each question answered yes
Miss PERT with >1 meal / week? 
Miss PERT with >2 snacks / week? 
Enzyme capsule split open? 
Do not carry enzyme around? 
Do not adjust PERT according to fat? 
STEP 2: PERT USAGE SCORE
Add scores from STEP 1.
  0-1 = Low risk
     2 = Medium risk
   3+ = High risk
STEP 3: BMI 
SCORE
BMI > 20 = 0
BMI 18.5 – 19.9 = 1
BMI <18.5 = 2
STEP 4: GI SCORE
No abdominal pain/loose stools/DIOS = 0
Intermittent abdominal pain/loose stools/DIOS = 1
Frequent abdominal pain/steatorrhoea/DIOS = 2
STEP 5: NUTRITIONAL STATUS SCORE
Add scores from STEPS 3 & 4.
   0 = Low risk
1-2 = Medium risk
 3+ = High risk
95• Patients with a high risk PERT usage score and low risk nutritional status score
require education / behavioural intervention.
• Patients with high risk in both aspects are the priority for dietetic intervention and
require strategies on adherence, education and nutritional support.
By assessing PERT practice in relation to nutritional status we can capture and identify risk
objectively   and  relatively   quickly.   This  may  help   us  to   be   more  effective  with  future
interventions. 
4.2.7 Education
A fine line may exist between optimal treatment management and the behavioural problems.
Therefore when considering future education plans, ensure that enzyme therapy doesn’t
become so regimented that it detracts patients from enjoying food. 
The data showed that the dietitian was the main source of advice on PERT although it was
evident that other health professionals and family also played a role. It is uncertain whether
information provided to patients is consistent and accurate, also whether patients find advice
from family supportive or detrimental. The study has identified a need for better patient written
communication for patients to take away and digest away from the busy clinic environment. It
is then important to follow this up they next time they attend clinic to ensure that they have
understood the advice and if they have any questions. Closer links are needed with
Paediatric CF Dietitians across the south west region to ensure coherent advice.
Evidence from the study of patient’s poor judgement at titrating PERT in accordance to the fat
content of food has prompted the development of patient resources. The ‘Pancreatic Enzyme
Adjustment Plan’ is devised by the dietitian based on the individual patient (see Appendix 13).
This has currently been trialled on a small number of patients to monitor effectiveness and
allow regular monitoring and ongoing adjustment. An individual’s recommended pancreatic
enzyme dose is easier to explain when it is stated as one capsule for a specific amount of
dietary fat (Stapleton et al 1999). This is done by dividing patients total daily enzyme capsule
dose by their fat intake (grams) to provide a specific amount of fat per capsule. The food diary
is ideal for calculating 5-day averages of daily fat intake and total enzyme dose. The example
in Appendix 13 shows that for this particular patient their estimated dose is 1 Creon 10,000 for
every 5g of fat. It is often found that by re-distributed enzyme capsules in accordance to the
fat content of foods, patients require less with certain foods and more with others. Also once
patients know their dose per quantity of fat, they can be used when referring to food labels.
96Having the plan has also enabled education on the varying fat content of food and that snacks
can contain as much fat as some meals. It has been strongly emphasised to patients that
assessment of PERT dose is still subject to trial and error. These patients will need
continuous follow up to adjust dose down or up over time. Patients are encouraged to bring
the plan in to clinic so that it can be updated with new foods. It is also vital that when patients
do not have their plans or a food label available for reference that they have the confidence to
judge for themselves what dose to take. A search through the literature revealed no published
evidence of work like this being done in the UK. Fat based doses are endorsed in the
Australian PERT guidelines but this is based on U lipase rather than capsule dose (Stapleton
et al 1999).
Gathering the fat contents of various foods has built up over time and this has been collated
into the ‘Fat Portion Reference Book’. This was initially developed for dietetic reference when
producing the ‘Pancreatic Enzyme Assessment Plan’. However, for patients who have had
their  PERT  dose per gram of fat estimated, this booklet provides them  with a more
comprehensive list of foods and drinks (see Appendix 14). These resources are still in the
early stages of development but once properly in use we have an obligation to evaluate the
effectiveness of intervention on patient knowledge and practice. 
Whilst this study is small in scale it has brought unique insights into PERT management. The
research is responding to patients needs by identifying where improvements are most
needed. Other clinical areas have been the inspiration to take the management of PERT
forward. Southampton dietitians have played a key role in the implementation of MUST
(Malnutrition Universal Screening Tool). This however has not been appropriate in the area of
CF as the dietitian is already aware of the patients. However the process of screening was
identified as being needed and a tool has been designed. The combination of patient’s PERT
usage and their nutritional status is expected to capture and identify patients at risk objectively
and quickly to allow resources to be allocated more effectively. 
Diabetes management is more advanced than CF in its provision of education for patients.
Carbohydrate counting is used in diabetes to promote better control and educate patients on
food values. A similar resource was developed with the ‘Fat portion reference Book’ so that
patients can titrate their enzymes more in accordance to the fat content of food.
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There are limitations that need to be acknowledged and addressed regarding the present
study. The first limitation concerns the  cross-sectional method, reflecting data that was
collected at one point in time. Unfortunately no study relying on patient reporting can exclude
social bias occurring. However attempts to reduce this were made by using an anonymous
system. All but 2 of the patients approached in clinic were willing to participate which shows
an excellent response rate. Twelve out of a total clinic population of 93 did not attend their
clinic population during the recruitment period. This raises the question as to who were the
missing potential study population. Patients who attend clinic are likely to be more motivated
than those who did not, therefore it could be presumed that adherence would have been
lower if the results were representative of an entire CF centre and that important information
was missed from this group of patients. The generalizability of the findings were restricted to
adults. However it was felt important to focus our attentions on those over the age of 16 years
as research in CF has predominantly focused on paediatric patients. 
Using a self-administered questionnaire allowed a large number of patients to be surveyed
within the clinic environment. Ideally, the study would have gone a stage further and included
interviewing patients but it was not possible to collate sufficient details on this prior to ethics
submission. Interviewing participants would have allowed verification the reliability and
validity of the questionnaire, and it is likely to have produced greater insight into individual
difficulties associated with PERT.
4.4 IMPLICATIONS OF THE RESEARCH FOR PROFESSIONAL PRACTICE
The initial hypothesis aimed to identify patient’s barriers to treatment, which in retrospect
implies that the problem of adherence lies with the patient. Much of this was due to general
ignorance of the patient’s perspective and frustration when they are unable to do everything
to   maximise   their   health.   It   has   become   increasingly   apparent   that   the   successful
management of PERT and other therapies is dependent on both the clinician and patient.
This study has reinforced how influential patient-provider communication can be and the need
to develop management beyond the traditional approach to a model that incorporates the
patient’s attitudes and beliefs. Many patients are under our care for their entire adult life. We
establish long working relationships with these patients and therefore have a responsibility to
get our health messages across. Patients may have had conflicting advice from health
professionals, relied on their parents for information or been reluctant to enquire about their
98treatment and disease. We therefore need to ensure that misconceptions patients have are
identified and then rectified so that their treatment knowledge is adequate. 
This study has enabled reflection of current practice and raised awareness of how it could be
improved. Prior to this study the focus was on completing procedures and delivering the
required advice, rather than actively listening to patients. We need to normalise non-
adherence, with clinicians addressing the demands of treatment burden and responding to
concerns specific to the individual.  Discussing difficulties surrounding  adherence more
openly, negotiating plans and prioritising treatments may be more advantageous than
patients doing their own thing intermittently. Also, acknowledging that patients aren’t fixed in
their state of adherence and depending on health and psychosocial factors there will be times
when they need greater and lesser support. 
More attention will now be directed towards how information is communicated to the patient
with emphasis and care to assure the patient has understood advice and that it can be
realistically achieved. Patients need information that speaks in clear terms that reflects what
matters to them, and prescribers need practical tools to use information in the consultation
(Jones 2003). It is no longer enough to provide patients with the most up to date evidence
based advice.  Whatever the strength of the evidence, no clinician can ever guarantee that
any particular patient will benefit from the treatment that he or she offers (Heath 2003). The
patient’s perspective on taking medication may differ greatly from those of clinicians. There is
increasing recognition among professionals working in CF that many of the challenges that
they and their patients face are psychological. The psychological aspects of adherence can
be   overwhelming   for   clinicians,   particularly   in   regard   to   the   different   approaches   to
management. We need to be prepared and have practical suggestions for overcoming
difficulties. This isn’t a straightforward process, as it requires time and negotiation. Verbal
advice should be backed up with written information where possible. 
4.5 DISSEMINATION OF RESEARCH FINDINGS
The primary aim of this project was to describe the enzyme practices of our clinic population in
an effort evaluate what our patients are doing and to identify future educational needs. This
project however also has a wider implication. The findings will be submitted as a research
paper to peer review journals and an abstract will be submitted for presentation at the
European CF Conference, with a potential interest in expanding this work to other regional
centres. 
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education and adherence. Although this study focused on the adherence to PERT, what has
been learnt is also applicable to the CF dietitian’s role in increasing calorie consumption,
adherence with nutritional supplements, vitamin therapy and the diabetic regimen.
4.6 SUGGESTIONS FOR FUTURE RESEARCH
There is no ‘gold standard’ measure of adherence to enzyme therapy in either the research
setting or clinical practice. Adherence is also difficult to evaluate due to the absence of
parameters on PERT control. Patients rarely volunteer details of non-adherence and so
strategies are needed that can reveal open and honest reporting from patients regarding their
enzyme use. For optimal management of pancreatic insufficiency, a non-invasive biomarker
is ideally required that can measure the consequences of changes in enzyme dose. For
example, if the enzyme prescription was too little or too much it would result in a biological
change that could be identified. Ideally a compound is required that can proportionally
measure enzyme dose in blood or urine. Objective quantitative measures of drug usage are
available for other treatments i.e. HbA1c levels to monitor insulin therapy. In the absence of
such tests for PERT we rely on the clinic consultation as the only mechanism to monitor
enzyme therapy. 
Several studies have identified adherence problems with PERT (Conway et al 1994, Abbott et
al 1994, McCabe 1996, Schall et al 2006) but there is a distinct lack of solutions to deal with
this issue. Progress has perhaps been hindered by a lack is definition as to what types of
enzyme practices are considered ‘good’ and where adherence matters the most. More
research is needed on how dietitians can best support patients with optimal adherence and
whether dietetic intervention can improve rates of adherence. Approaches to changing
behaviour need to be investigated and trialed within this patient group. Consideration into the
ease of use within the clinic environment is essential. 
Further research will be required to evaluate whether improving patient resources and
structured education results in a more effective understanding of how PERT should be used
by the patient. In line with the SUHT Patient Experience Strategy, there is an emphasis on
taking patients needs into greater consideration. Through enhanced patient participation (i.e.
100negotiating plans) and satisfaction with this aspect of care, change in attitudes and behaviour
that optimise PERT usage and improves clinical outcome.
4.7 CONCLUSIONS
The goal was to improve the assessment and management of adult CF patients with
pancreatic insufficiency. A questionnaire was created to provide the CF dietitian with a tool to
measure patient knowledge and adherence to the PERT regime and how this compares with
recommendations for best practice. A set of potentially better practices were identified. Our
understanding has increased greatly due to the views expressed by patients. Knowing more
about patient’s experiences and difficulties are key to future interventions.  This work has also
had wider implications, as the issue of adherence is relevant to all areas of CF, which has led
the care team to also reflect on their management practice.
Target areas for intervention and establishing best practice guidelines for PERT
1. On transition to the adult service from paediatrics and at the initial assessment of
newly referred patients ensure that there is sufficient time available to establish a
rapport and thoroughly assess enzyme practices. There are certain questions that if
phrased  adequately  and  sensitively   need  only  be  addressed once  i.e.  whether
enzymes are split open, ability to swallow capsules whole, whether they count out their
dose or estimate.
2. Use the annual review to monitor PERT use for current patients. Trial the use of the
adherence category criteria in appendix 12 to see whether patients reveal in greater
detail the extent to which they miss PERT with meals and snacks. 
3. Produce a quiz for patients to complete whilst they are waiting to be seen in clinic.
Include questions on dosage, frequency,  adverse  effects of non-adherence etc.
Patients can get answers from the quiz when they see the dietitian. This tool could
assess   misconceptions   and   gaps   in   knowledge   and   advice   can   be   addressed
accordingly. As it is the patients who are ultimately left to self-titrate their enzyme
therapy, they may want to know more about if what they are doing is correct so
feedback is essential.
4. Educate all patients on varying their PERT in accordance to the fat content of food and
drink with the aim to prevent either the under or over use of lipase. Provide written
advice to back up verbal instructions - ‘Pancreatic Enzyme Adjustment Plan’ and / or
guidance on the ‘Fat Portion Reference Book’.  
1015. Seek advice from a CF psychologist on ways to optimize strategies for adherence to
PERT.  Produce a patient information sheet on practical ways for dealing with the
embarrassment and forgetfulness associated with PERT.  We need to take more
consideration of patient’s lifestyle and ask how they manage their enzymes in difficult
situations. 
6. Provide teaching sessions to the multidisciplinary team and written advice for partners
and families of patients with CF to ensure consistent advice on PERT.
7. Certain things are within our control such as simplifying the treatment regimen where
possible and developing our communication skills to identify and deal with patient’s
difficulties surrounding their PERT. 
8. Trial the Assessment tool and devise an action plan for management.
9. Acknowledge patients own beliefs and attitudes and recognise the constraints and
barriers   that   influence   their   ability   to   take   PERT   optimally.   Further   investigate
counselling / motivational interviewing skills.
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APPENDIX 1: DETERMINATION OF CF ENERGY REQUIREMENTS
DEE = BMR x (activity coefficient + disease coefficiency)
Age range Females Males
0 – 3y 61.0wt - 51 60.9wt – 54
3 – 10y 22.5wt + 499 22.7wt + 495
10 – 18y 12.2wt + 746 17.5wt + 651
18 – 30y 14.7wt + 496 15.3wt +679
30 - 60y 8.7wt + 829 11.6wt + 879
Activity coefficients:-
1.3 – confined to bed
1.5 – sedentary
1.7 – active
Disease coefficents:-
0 - FEV1 >80% predicted
0.2 – FEV1 40 – 79% predicted
0.3 – FEV1 <40% predicted
Stool losses:-
Pancreatic sufficient patients: DER + DEE
or
Pancreatic insufficient patients: DER x 1.1 = DEE
(where stool fat collections are not available)
World Health Organisations
Energy and Protein Requirements
WHO Tech. Rep. Ser, No. 724 1985;000
103APPENDIX 2: Summary of the nutritional recommendations – Nutritional management
consensus report 2002
Assessment of growth and nutritional status
Weight should be recorded at every clinic visit.
For adults, measurements should be converted to body mass index.
Recommendations for pancreatic enzyme supplementation
Acid resistant pancreatin microspheres or minimicrosphere preparations are recommended
for infants when intestinal malabsorption and pancreatic insufficiency are confirmed.
Dosages should not exceed 10,000 IU lipase/kg bodyweight / day. 
Dividing the pancreatin dose between the beginning, middle and end of the feed may
promote better mixing of pancreatin and chyme and can anticipate normal variations in
appetite.
Individual assessment of nutritional needs should be reviewed regularly by a dietitian
experienced in CF and modified, according to the changing clinical and psychosocial needs
of the patient. 
General recommendations for vitamin supplementation
Supplemental vitamin A, D and E should be  commenced on diagnosis of  pancreatic
insufficient patients with cystic fibrosis.
Plasma fat-soluble vitamin levels should be measured as part of the Annual Review and the
supplement dose adjusted according to plasma levels.
Pancreatic sufficient patients should also be monitored by measuring serum levels annually.
Supplemental vitamin A, D, E should be commenced when low levels are detected.
Vitamin A recommendations:
Retinol binding protein and plasma zinc may aid interpretation of low plasma levels although
are not required for all patients.
Dose:
-<1 year:4,000IU (1,200mcg) daily
->1 year: 4,000 to 10,000 IU (1,200 to 3,000 mcg) daily.
104Vitamin D recommendations:
There should be awareness of seasonal variations in levels.
Dose:
-Infants:400IU (10mcg) daily
-Children: 400 to 800 IU (10 to 20 mcg) daily
-Adults: 800 to 2,000 IU (20 to 50 mcg) daily.
Vitamin E recommendations:
Plasma vitamin E/lipid ratio is essential for the accurate interpretation of low vitamin E levels.
Dose:
-Birth to 1 year: 10 to 50 mg daily
-1 year to 10 years: 50 to 100mg daily
-10 years: 100 to 200 mg daily.
Vitamin K recommendations:
Assessment by prothrombin levels (although levels do not correlate well with plasma vitamin
K levels).
Factor II coagulant activity / factor II antigen ratio (normal 0.85 to 1.0) is useful.
Monitor prothrombin levels as an indicator of vitamin K status at Annual Review if liver
disease is present or suspected or following intestinal resection.
Recommended dose is not established; suggested children and adults receive vitamin K 10
mg daily.
Invasive nutritional support
Use of enteral and parenteral feeds should always conform to local policies and guidelines.
Regular nutritional assessment and, when required, nutritional support should be an integral
part of overall care.
Invasive nutritional support should be considered when oral methods of maintaining an
acceptable nutritional status have failed.
Indications for nutritional support include: for adults BMI<19, despite intensive use of oral
supplements or a poor weight gain during pregnancy.
Recommendations for routine dietary therapy of CFRD
Combine the elements of the cystic fibrosis and diabetes mellitus diet.
Any dietary conflict should be resolved in favour of CF diet.
105APPENDIX 3: BMI CLASSIFICATION
BMI Classification (WHO, 1998)
<18.5 Underweight
18.5 24.9 Ideal
25-29.9  Overweight
106APPENDIX 4: PANCREATIC FUNCTION AND MUTATIONS 
(Cystic Fibrosis Foundation 2001)
Pancreatic-Sufficient Variable Pancreatic-Sufficient
Dominant CF Mutations CF Mutations
G551S G85E
P574H R347P
R117H 3849 + 10kb C → T
R334W A445E
R347H 2789 5G → A
R352Q
T3381
107APPENDIX 5: MINIMUM ENZYME CONTENT (BP UNITS) OF PANCREATIN
PREPARATIONS
(CF Trust 2002)
Name Maker Lipase Protease Amylase
Enteric-coated microspheres
Nutrizym GR Merck 10,000 650 10,000
Pancrease Janssen Cilag 5,000 330 2,900
Enteric coated minimicrospheres
Enteric-coated microtablets
Nutrizym 22 Merck 22,000 1,100 19,800
Nutrizym 10 Merck 10,000 500 9,000
Pancrease HL Janssen Cilag 25,000 1250 22,500
Cotazym S Organon 8000 30,000 30,000
Other enzyme preparations available in the UK
Name Maker Lipase Protease Amylase
Pancrex V
Forte Tablets
Enteric coated
tablets
Paine & Byrne 5,600 330 5000
Pancrex V
Tablets
Enteric coated
tablets
Paine & Byrne 1900 110 1700
Pancrex V
capsules
Capsules
Paine & Byrne 8000 430 9000
Pancrex V
capsules ‘125’
Clear capsules
Paine & Byrne 2950 160 3300
Pancrex V
Powder
Buff powder
Paine & Byrne 2500 1400 30000
Pancrex
granules
Coated
granules
Paine & Byrne 5000 300 4000
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Creon 10,000 Solvay 10,000 600 8,000
Creon 25,000 Solvay 25,000 1000 18,000
Creon 40,000 Solvay 40,000 1600 25,000APPENDIX 6: ETHICS APPLICATION
109APPENDIX 7: DATA PROTECTION
110APPENDIX 8: LETTER OF INVITATION
111APPENDIX 9: PATIENT INFORMATION SHEET
112What do I have to do?
This research project will not require you to make any changes to your medication or lifestyle.
The questionnaire only needs to be completed once.
What are the possible benefits of taking part?
The information that we get from this study may help us to provide patients with more realistic
advice and improve the communication process between health professionals and patients.
Will my taking part in this study be kept confidential?
All information which is collected in the questionnaire will be kept strictly confidential and
stored securely. Names will not be added to the questionnaire so that on completion the
investigator will not be aware of who made individual comments.
What will happen to the results of the study?
This research project will be analysed and written up into a thesis towards a postgraduate
master’s degree. The results may be published in journals relevant to Cystic Fibrosis care so
that colleagues can be aware of this work. Details of this project will also be included in a
patient newsletter and sent out to all the patients attending this service. Your name will not be
identified in any report or publication. 
Who is organising and funding this research?
This research is being conducted by Clare Pearson and no payment is involved for including
and looking after the participants of this study. A Research and Development Fellowship has
been awarded to allow time for this project to be carried out. 
Who has reviewed this study?
The Southampton Research Ethics Committee has reviewed this study.
Contact for further information
If you would like to ask any questions please do not hesitate to make contact.
Many thanks for taking the time to read this and consider the details of the project.
Yours Sincerely
Clare Pearson – Senior Dietitian
Southampton Adult CF Team
Telephone 023 80796801
113APPENDIX 10: CONSENT FORM
114APPENDIX 11: QUESTIONNAIRE
115116117118119120121APPENDIX 12: CLASSIFICATION OF ADHERENCE
Taken with
every meal
Miss with
1-2 
Miss 3-5
times
Miss 6-9 Miss >10
times
Do not take
Taken with
every
snack
0 1 1 1 2 2
Miss 1-2
times
0 1 1 1 2 2
Miss 3-5
times
0 1 1 1 2 2
Miss 6-9
times
1 1 1 2 2 2
Miss > 10
times
1 1 2 2 2 2
Do not
take
2 2 2 2 2 2
0 = adherent
1 = partially adherent
2 = non-adherent
frequency meals * frequency snacks Crosstabulation
Count
17 8 4 3 0 1 33
0 4 6 0 0 3 13
0 0 1 1 0 0 2
0 0 0 0 1 0 1
17 12 11 4 1 4 49
taken every meal
miss 1-2 meals
miss 3-5
miss 6-9
frequency
meals
Total
taken every
snack
miss 1-2
snacks miss 3-5 miss 6-9 miss >10 do not take
frequency snacks
Total
122APPENDIX 13: FAT PORTION REFERENCE BOOK
FAT PORTION
REFERENCE BOOK
Fat contents of foods for managing Pancreatic
Enzyme Replacement Therapy
Name: ................................................................
Date: ................................................................
Dietitian: ................................................................
 No: ................................................................
123HOW TO USE THE FAT PORTION BOOKLET
Requirements   of   pancreatic   enzyme   replacement   therapy   vary   widely   between
individuals. Prior to being given this booklet your dietitian will have discussed your
recommended dose with you, this can be added below:
This booklet is intended to be a convenient source of information on the fat contents
of commonly consumed foods. These details can help determine the quantity of
pancreatic enzymes required with different food and drink to enable you to adjust your
enzyme dose more effectively.  Fat content varies considerably between foods and
even between brands, therefore once you have become established with this new
way of managing your enzyme therapy, it is worth looking at the labels of foods you
commonly eat and include them in ‘My Section’ at the end of this booklet. 
The lists show:
1) Food and drink per category
2) Portion sizes. This has been included for convenience and is based on
average portion sizes. Some foods are easier to classify into portions than
others e.g. 1 weetabix biscuit. 
3) The average fat value per 100g is also shown. Values can differ between
products. More information is available from food labels remember to use the
TOTAL fat content. 
To work out the fat content using the amount of fat per 100g on a food label, use the
following equation:
amount of fat (g) in the portion = weight of food (g) x fat content (g) per 100g  
                                                                100
Weight conversion:
½ oz = 15g
1oz = 25g
2oz 50g
3oz = 75g
4oz = 100g
1 teaspoon = 5ml
1 tablespoon =15ml
5fl oz (1/4 pint) = 150 mls
10 fl oz (1/5 pint) = 275 mls
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1 capsule of  ............... per ..... g of fatThe science bit..... 
Digestion is the breakdown of food into smaller molecules, so that it can pass through
the wall of the gut for absorption. Digestion starts in the mouth by an enzyme called
amylase, which is found in saliva. Amylase breaks down carbohydrates (starches)
into sugar. In the stomach, gastric juices contain another enzyme called protease,
which begins the digestion of protein to amino acids.  Lipase is the final enzyme,
which breaks down fat. Lipase is made in the pancreas, which  is affected in CF
patients with pancreatic insufficiency. Pancreatic enzyme capsules contain all 3 of
these enzymes but it is particularly fat that needs ‘a helping hand’. Enzymes are
therefore required with all food and drink containing fat. 
 
Beverages
The following cold drinks do not contain fat therefore no enzymes are required: fizzy
drinks, flavoured water, fruit juice, juice (i.e. Capri sun, Sunny Delight, Fruit shoots,
Squash), water, milkshake powders (Nesquick) and syrups (Crusha) contain only
traces of fat). 
Coffee and tea       
Contain a small amount of milk but the fat content within this is minor. If you are
having milky coffee or hot chocolate made up with milk instead of hot water, use the
takeaway guide below. 
Alcoholic drinks mostly do not contain fat; the exceptions are cream based liquors
and cocktails containing cream. As a guide take as many enzymes as you would with
the same volume of cream. 
Food Item Typical Portion Size Fat per Portion Fat per 100g
Full fat milk 200mls (1/3 pint) 8 4g
Semi-skimmed milk 200mls (1/3 pint) 4 2g
Skimmed milk 200mls (1/3 pint) 0 0g
Frijj Milkshake  per 100ml 2g 2g
Splat Milkshake per 100mls 1g 1g
Yop Yogurt Drink per 100ml 1g 1g
Cappuccino, whole milk Mug/‘Tall’ size at Starbucks 6g
‘Grande’ 8g
Latte, whole milk Mug/‘Tall’ Starbucks 11g
‘Grande’ 14g
Mocha with cream Mug/‘Tall’ Starbucks 17g
‘Grande’ 21g
Hot chocolate & cream Mug/ ‘Tall’ Starbucks 19g
Grande 24g
125Breads, pasta, rice & breakfast cereal
These foods on their own contains only a very small amount of fat, therefore shouldn’t
require   enzymes   unless   were   eating   large   quantities.   Adding   such   things   as
margarine, butter, cheese or milk makes these foods more palatable and increases
the energy content of food. To work out the fat content of these foods base it on these
additions only (see sections on spreads, milk and cheese). 
Biscuits
Food Item Typical Portion Size Fat per Portion Fat per 100g
Chocolate Chip Cookies 8g each 2 23
Custard cream 11g each 2 21
Digestive Biscuit 1 biscuit, 13g each 3 20
Full chocolate coated 1 biscuit, 18g each 4 24
Jaffa Cake 1 cake, 13g each 1 8
Penguin Biscuit 25g 7 28
Plain e.g. Rich Tea 1 biscuit, 7g 1 13
Buns & Cakes   
Food Item Typical Portion Size Fat per Portion Fat per 100g
American Muffins 85g 15 18
Mini-muffins, chocolate 28g 5 18
Bakewell tart, individual 43g 9 20
Black Forest Gateau 90g slice 7 16
Chocolate Fudge Cake 65g slice 5 8
Cupcakes, iced 41g 2 5
Chocolate Eclair 90g 28 31
Currant Bun 60g 3 6
Custard tart, individual 94g 14 15
Danish pastry (medium) 110g 15 14
Doughnut, jam filling 75g 11 15
Flapjack (med) 60g 16 26
Fruit Cake  90g 12 13
Malt Loaf 35g slice, without butter 1 2
Mince Pie, individual           55g 12 21
Mini-roll 25g 5 21
Sponge, with butter icing 60g slice 19 31
Swiss Roll, chocolate 30g slice 5 17
Butter and margarines
Food Item Typical Portion Size Fat per Portion Fat per 100g
Butter/hard margarine
- thickly spread on slice of bread 10g 8 82
- 1 portion, packed 10g 8 82
- 1 teaspoon 5g 4 82
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Food Item Typical Portion Size Fat per Portion Fat per 100g
Brie/Camembert Average portion, 40g 12 29
Cheddar 1 tablespoon grated, 10g 4 35
In sandwich, 45g 16 35
Processed Cheese  1 Slice, 20g 5 23
Confectionery
The following sweets do not contain fat therefore do not require enzymes: Barley
sugar, Boiled Sweets, Mints, Fruit gums/jellies, Fruit Pastilles, Jellies, Kola Cubes,
Lockets, Marshmallows, Pear Drops, Polo Fruits, Refreshers, Sherbet Fountain,
Sherbet Lemons, Tunes, Turkish Delight (without nuts or chocolate), Wine Gums.
Food Item Typical Portion Size Fat per Portion Fat per 100g
Aero Bar bar, 48g 15 31
Bounty 57g twin pack 15 26
Chocolate Buttons standard packet, 33g 10 31
Chocolate nuts, M&M’s 47g packet 13 27
Crunchie 40g bar 8 20
Curlie Wurly 26g 5 19
Dairy Milk 43g 13 31
Flake bar 32g 10 31
   in 99 ice-cream 9g 3 31
Galaxy 47g bar 15 31
Kit Kat 49g 4 fingers 13 26
Lion bar standard size, 55g 14 25
Mars kingsize, 100g 18 18
standard, 65g 12 18
snack, 42g 8 18
funsize, 19g 3 18
Milky Way 26g bar 4 17
M&M’s – plain 45g packet 9 21
Quality Street, roses 8g each 6 25
Rolo 53g tube 10 20
Smarties 40g tube 7 17
Snickers 61g bar 17 28
Toffee Crisp 44g bar 12 28
Fruit
No enzymes required if you are just having a piece of fruit. However, if you are having
fruit as part of a pudding i.e. fruit pie or fruit and cream, see the ‘Pudding’ and ‘Milk &
milk products’ sections.
Fish
Food Item Typical Portion Size Fat per Portion Fat per 100g
127Cod, in batter Medium, 180g 18 10
Fish cakes 1 fried, 100g 10 10
Fish fingers, fried 1 finger, 28g 13 13
Fish fingers, grilled 1 finger, 28g 9 9
Fish pie (fish & potato) 250g 8 3
Haddock, breadcrumbed 120g 10 8
Haddock, fried in batter medium 170g 14 8
Scampi, in beadcrumbs Average portion, 170g 31 18
Meat Products
Food Item Typical Portion Size Fat per Portion Fat per 100g
Bacon, 2 rashers, fried 25g average 20 40
Beefburger, no bun 36g 6 17
Beef, roasted medium portion, 90g 11 12
Beef, roasted  1 thick slice 45g 5 12
Chicken, roasted 1 slice, breast 40g 2   5
Chicken leg edible portion, 47g 1 3
Ham 23g 1   4
Pate, Brussels 30g 9 29
Steak & Kidney Pie 1 individual (160g) 34 21
Sausage Roll Medium (80g) 29 36
Pork pie Individual (140g) 38 27
Cornish Pastie Medium, 155g 31 20
Milk & Milk Products
Food Item Typical Portion Size Fat per Portion Fat per 100g
Evaporated milk 90 mls 8 9g
Cream, double, whipped 1 tablespoon, 30g 14 48g
Cream, single 1 tablespoon, 15g 3 19g
Yogurt 125g pot 4 3
Low fat yogurt 125g pot 1 1
Custard made up average portion, 120g 7 6
Rice pudding Average portion (150g) 5 3
Icecream 1 scoop, 60g 6 10
Choc Ice Individual (52g) 15 28
Puddings
Food Item Typical Portion Size Fat per Portion Fat per 100g
Cheese cake average slice, 120g 19 16
Crumble, any fruit average portion, 170g 12 7
Custard, canned average portion, 120g 7 6
Chocolate mousse individual, 60g 3 5
Fruit pie average portion, 110g 14 13
Profiteroles average portion, 155g 40 26
Sponge Pudding average portion, 110g 18 16
Fast Food /Takeaways
McDonalds
Food Item Typical Portion Size Fat per Portion Fat per 100g
128Big Breakfast 273g 35 13
Big Mac 216g 24 11
Cheeseburger 118g 12 10
Chicken McNuggets  6 pieces, 104g 14 13
Cheese quarter pounder    195g            25 13
Double cheeseburger 170g 22 13
Fillet-O-Fish 147g 16 11
French Fries  small, 80g 12 15
French fries  medium, 114g 17 15
French Fries  large, 160g 23 14
Hamburger 104g 8 8
McChicken Sandwich 170g 16 9
McFlurry 185g 11 6
Milkshake medium, 336g 10 3
Burger King
Food Item Typical Portion Size Fat per Portion Fat per 100g
XL Double Whopper 355g 50g 14
Whopper 274g 34g 12
Hamburger 117g 11g 9
Cheeseburger 130g 14g 11
Double Cheeseburger 185g 27g 15
Bacon Double Cheeseburger 172g 28g 16
Chicken Royale  210g 32g 15
Spicey Beanburger 247g 20g 8
Veggie Burger 230g 15g 7
Fries small 74g 10g 14
Fries reg      116g 15g 13
Fries super 174g 19g 11
Onion rings reg        90g 13g 14
Diddy Donuts    84g 8g 10
Dairy Ice Cream Shake regular 124g 6g 5
Pizza Hut
Food Item Typical Portion Size Fat per Portion Fat per 100g
Garlic Bread 4 slice portion 16g 13
Garlic Bread with Cheese   4 slice portion 32g 17
Garlic mushrooms per serving 10g 8
Potato wedges per serving 14g 6
Hawaiian  Medium Pan, per slice 8g 8
Margherita  Medium Pan, per slice 10g 10
Vegetarian Original  Medium Pan, per slice 8g 8
Meat Feast  Medium Pan, per slice 13g 13
Stuffed Crust Margarita per slice 12g 9
Domino’s Pizza
Food Item Typical Portion Size Fat per Portion Fat per 100g
Garlic Pizza Bread per portion as sold, 214g 5g 9
129Potato wedges per portion as sold, 165g 11 7
Cheese and Tomato 9.5” per slice, medium 54g 3g 5
Deluxe 9.5” per slice, medium 77g 6 8
Full House 9.5” per slice, medium 84g 7g 9
Pepperoni Passion 9.5” per slice, medium 82g  9g 8
Vegetarian Supreme 9.5” per slice, medium 81g 2g 3
Fish & Chips
Food Item Typical Portion Size Fat per Portion Fat per 100g
Cod, in batter fried Medium, 180g 18 10
Chips, fried in oil average portion, 165g ` 20 12
Indian
Food Item Typical Portion Size Fat per Portion Fat per 100g
Chick pea dahl average, 210g 13 6g
Chicken tikka masala 260g 29 11
Lamb Korma 260g 21 8
Meat Biriani 400g 35 9
Lamb Rogan Josh 350g 30 9
Naan bread 1 piece, 60g   8 13
Rice, boiled or steamed medium portion, 180g                     2  1
Rice, fried medium potion, 180g   7 4
Samosa, meat 80g each 44 55
Samosa, vegetable 80g each 34 43
Thai
Food Item Typical Portion Size Fat per Portion Fat per 100g
Thai chicken curry 180g  36 20
Beef curry  260g 18 7
Satay beef 30 4 13
Satay, pork 30 7 23
Stir-fried vegetables 200 8 4
Thai rice noodles 280g 3 1
Chinese
Food Item Typical Portion Size Fat per Portion Fat per 100g
Beef in black bean sauce 260g 10 4
Beef chow mein 260g 16 6
Lemon chicken 260g 8 3
Pork, BBQ 230g 35 15
Pork spareribs 100g 10 10
Prawn crackers         Takeaway portion, 70g 27 39
Prawn szechuan 260g 16 5
Rice, fried 1 cup, 165g 14 8
Spring rolls, fried small, each 60g 5 8
Sweet & sour pork 260g 23 9
Sandwiches
Food Item Typical Portion Size Fat per Portion Fat per 100g
130Egg Mayonnaise & Cress per pack 10
Cheese & Pickle per pack 8
Ham, Cheese & Pickle per pack 8
Prawn Mayonnaise per pack 12
Roast Chicken Salad per pack 6
Salmon & Cucumber per pack 11
Tuna & Sweetcorn per pack 5
Crisps & savoury snacks
Food Item Typical Portion Size Fat per Portion Fat per 100g
Bombay Mix   average portion, 30g 10 33
Cashews, roasted & salted medium bag, 50g  26 51
Crisps per 34.5g pack 8 10
Doritos per 40g pack 11 28
French Fries per 22g pack 4g 18
Hula Hoops per 27g pack 8.5 31
Kettle Chips average portion, 50g 13 27
Monster Munch per 25g pack 6 24
Peanuts, roasted & salted medium bag, 50g 27 53
Popcorn, plain 25g 11 43
Pork scratchings 22g bag 10 46
Pringles 50g 19 38
Skips per 17g pack 5 29
Twiglets 50g bag 6 12
Wotsits per 21g pack 7 33
Main meals
Food Item Typical Portion Size Fat per Portion Fat per 100g
Bean Burger 155g, without bun 17 11
Beef Stew Medium portion, 140g 7 5
Bolognese Sauce average portion, 240g 29 12
Casserole, Sausage medium portion, 260g 29 11
Chicken Kiev per Kiev, 170g 36 21
Chilli Con Carne 220g, without rice 18 8
Chops, Lamb average chop, 120g 26 22
Chops, Pork average with bone, 150g 9 6
Curry, Beef average, 350g 25 7
Curry, Lamb average, 350g 11 13
Curry, Chick pea dahl average, 210g 13 6
Fish fingers, fried 1 finger, 28g 13 13
Fish fingers, grilled 1 finger, 28g 9 9
Fish pie (fish & potato) 250g 8 3
Haddock, breadcrumbed 120g 10 8
Haddock, fried in batter medium 170g 14 8
Gammon steak 1 steak, average 170g 20 12
Kedgeree average portion, 300g 27 9
Lancashire Hotpot 260g 18         7
Lasagna 420g 46         11
131Macaroni Cheese average portion, 220g 22 10
Omelette, Cheese 2 eggs, 120g 28 23
Quiche Lorraine medium portion, 140g    36 26
Sausages, pork 2 large, fried, 80g 20 25
Scampi, in breadcrumbs Average portion, 170g 31 8
Shepherds/ Cottage Pie  average portion, 310g 19 6
Steak, rump 5oz / 103g, fried 15 15
8oz /166g, fried 25 15
Vegetable accompaniments
Food Item Typical Portion Size Fat per Portion Fat per 100g
Cauliflower cheese side dish, 90g 6 7
Coleslaw 1 tablespoon, 45g 12 26
Potatoes, roasted  1 medium potato, 85g 4 5
Potatoes, mashed – butter 1 scoop, 60g 2 4
Chips, oven medium portion, 165g 7 4
Chips, homemade fried medium portion, 165g 12 7
Potato wedges 165g 8 5
Potato waffles 1 waffle grilled, 45g 4 8
Potato Croquettes 1 average, grilled 80g 2 2
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3    Creon    
Scoops of ice-cream x 2
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Level D, Mailpoint 32 
Southampton General Hospital 
Tremona Road 
Southampton 
SO16 6YD 
Tel: 023 8079 6072 
Fax: 023 8079 8665 
PANCREATIC ENZYME PLAN 
 
 
 
Name:           Dob:  
Hospital No:  
 
This plan is based on the goods and drinks that you have provided in your food diaries. 
The information below provides guidance on how to adjust your pancreatic enzymes in 
accordance with the fat content of your diet. Your individual estimated dose is 1 
Creon 10,000 for every 5g fat. However this can only be worked out  ‘approximately’ 
therefore do not worry if you are eating out or there are no food labels are available, 
just use your judgement of what you would take for a similar food. Please bring this list 
to  outpatient  clinic  and  hospital  admissions  so  that  we  can  update  new  foods  as 
appropriate. Do not hesitate to contact me if you are unsure about anything. 
 
Clare Pearson 
Adult CF Dietitian 
023 80796801 
 
0 Creon    
Fizzy drinks 
Fruit 
 
 
1 Creon 
Chicken roll 
Portion mashed potato 
Yoghurt (unless low fat or diet) 
Bowl of cereal with milk 
2 digestive biscuits 
 
 
2 Creon 
½ pint whole milk 
Mars bar (54g) 
TUC biscuits x 2 
Packet of crisps (30g) 
Sausages x 2 
Cheese roll 
Fishfingers: fried x 2 Fruit pie (100g)
Chocolate biscuits x 3
Fish cooked in batter i.e. cod
Pot Noodle
4    Creon    
Portion of homemade/takeway chips
Chille & rice
Curry & rice
Chocolate muffin
5    Creon    
Roast dinner
Peanuts 50g
6    Creon    
Takeaway burger & fries
Cheese & onion slice (180g)
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